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1.  ABSTRACT    
  
Doberman hepatitis (DH) is a chronic liver disease which is usually diagnosed when the 
dog has clinical signs of liver failure. At this stage of the disease, the prognosis is poor. 
Detection of affected individuals in the asymptomatic subclinical stage would likely 
improve survival time. To date, diagnosis of subclinical DH has been difficult since 
criteria for this stage are lacking and the etiopathogenesis of DH is unknown.  
 
The aim of this work was manifold. First, the serum parameters most effective for 
screening subclinical DH and indicating progression from the subclinical stage to the 
clinical stage were determined. Second, the histopathological lesions in the subclinical 
stage of DH were described. Third, the role of increased hepatic copper (Cu) in DH was 
studied. And, fourth, the etiology and the pathogenesis of DH were evaluated based on 
the observation that hepatocytes in DH express major histocompatibility complex 
(MHC) class II molecules.    
 
Serum concentrations of both alanine aminotransferase (ALT) and alkaline phosphatase 
(AP) are routinely used to detect liver failure in dogs. Based on the findings from the 
first phase of this study, ALT was determined to be the more reliable liver enzyme in 
detecting subclinical DH. During the early stage of the disease elevated concentrations 
of ALT can be seen, followed by an increase in AP. Serum concentrations of ALT and 
AP were shown to be abnormally high for several months or even years before onset of 
clinical signs of DH. Fluctuation of these parameters was common during the 
subclinical stage, while total bilirubin concentration in serum remained normal. An 
increase in total bilirubin was therefore deemed to be the best serum parameter for 
predicting the disease’s progression to the clinical stage. 
 
In the second phase of the study, the most characteristic histological findings during the 
subclinical stage were parenchymal and portal inflammation. The inflammatory cells 
were mostly lymphocytes and macrophages, with neutrophils and plasma cells being 
few in number. Periportal inflammation was minimal. Bridging necrosis was also 
seldom observed. A scoring system was used to determine how histological lesions in 
biopsy differed from  those in autopsy liver samples of the same dog. With this system, 
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DH was shown to be progressive in nature. When clinical signs appear, the histological 
findings resemble those typical of chronic hepatitis with piecemeal and bridging 
necrosis, fibrosis, and cirrhosis. 
  
During the third phase of this study elevated hepatic Cu content was recorded both in 
the subclinical and clinical stages of DH. In the subclinical stage, the location of Cu was 
first observed  in hepatocytes in the parenchymal area. Periportal areas were mainly 
intact. In the clinical stage, the Cu was mostly located adjacent to piece-meal and 
bridging necrosis areas. No intrahepatic cholestasis was evident, bile plugs were  
observed  very rarely, and serum total bilirubin values were within the normal range 
during the subclinical stage of DH. Increased hepatic Cu content was also demonstrated 
to be associated with inflammation of the tissue. Based on these findings, Cu 
accumulation in hepatocytes was speculated to be caused by mononuclear 
inflammation, which in turn disturbs the secretion of Cu from hepatocytes to the bile 
canaliculus.  
 
From the combined findings of the first three study phases, the diagnosis of subclinical 
DH was determined to be based on the following four criteria: 1) the dog is clinically 
asymptomatic; 2) the dog has an elevated serum ALT concentration that is at least three 
times above the normal upper value in two consecutive blood samples; 3) mononuclear 
inflammation is present in the liver; 4) increased hepatic Cu content is detected by a 
special stain. 
 
Since normal hepatocytes do not express MHC class II molecules, their expression in 
hepatocytes in DH indicates that hepatocytes are the target cells of this disease. The 
etiological background of DH was analyzed in the fourth phase of this study based on 
findings of abnormal MHC class II expression in hepatocytes during  different stages of 
DH. MHC class II molecules were expressed in hepatocytes in 87% of biopsies taken 
during the subclinical stage of the disease and in 100% of autopsy cases. This finding is 
a strong indicator of the autoimmune background of DH. 
  
A significant correlation between mononuclear inflammation and MHC class II 
expression in hepatocytes was also noted. This finding suggests that cytokines produced 
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by mononuclear inflammatory cells could induce abnormal MHC class II expression in 
hepatocytes.  
 
Staining patterns of  MHC class II expression in hepatocytes vary according to the stage 
of the disease. In the subclinical stage, expression was observed to be mostly 
cytoplasmic, whereas in the clinical stage molecules were detected mainly on the cell 
membrane. These findings indicate that while the MHC class II molecule and antigen 
are in the cytoplasm, the hepatocyte is protected from the immune system. However, as 
soon as the MHC class II:autoantigen complex reaches the cell surface, the immune 
system will recognize  the autoantigen and be activated. 
 
Thus in DH , the MHC class II molecule apparently presents an autoantigen to the 
CD4+ T-cell, which in turn becomes activated, initiating the immune attack against 
hepatocytes. The T-cells are therefore autoreactive and DH is a T-cell-mediated disease. 
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3.  ABBREVIATIONS   
 
ALT  alanine aminotransferase  
ANA  antinuclear antigen 
AP  alkaline phosphatase  
APC  antigen-presenting cell  
BSA  bovine serum albumin  
CAH  chronic active hepatitis 
CAV-1 canine adenovirus-1   
Cu  copper 
DH  Doberman hepatitis 
DNA  deoxyribonucleic acid 
dw  dry weight  
ER  endoplasmatic reticulum 
HAI  histology activity index 
HBV  hepatitis B virus 
HCV  hepatitis C virus  
HE  hematoxylin and eosin 
HNO3  nitric acid 
HRP  horseradish peroxidase 
LKM  liver kidney microsome   
LMA  liver membrane antibody   
MHC major histocompatibility 
complex  
mmol/L millimole/liter   
PBC  primary biliary cirrhosis 
SD  standard deviation  
SMA  smooth muscle antigen 
TBS  Tris Buffer Saline   
U/l  Unit/liter 
VG  van Gieson   
α-1-A alfa-1- antitypsin 
CD  cluster of differentation 
PAS  peroxid acid stiff 
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4.  INTRODUCTION      
 
Chronic hepatitis in dogs refers to a chronic inflammatory process that destroys the liver 
parenchyma, resulting in liver failure (Strombeck and Gribble 1978, Sarli 1992). In 
dogs, chronic hepatitis is among reactive hepatopathies the most commonly diagnosed 
liver disorders (Twedt 1998b). Certain breeds, such as Bedlington Terriers, West 
Highland White Terriers, Cocker Spaniels, Labrador Retrievers, and Doberman 
Pinschers are more prone to chronic hepatitis than other breeds (Twedt et al. 1979, 
Doige and Lester 1981, Sevelius  1995,  Thornburg et al.1996, Fuentealba et al. 1997). 
 
In the literature, different names can be found for chronic hepatitis in Dobermans. 
‘’Chronic active hepatitis’’, formerly the predominant term, was adapted from the 
terminology for human hepatitis (Meyer et al. 1980, Fiorito 1985, van den Ingh et al. 
1988, Searle 1991). The initial classification of chronic hepatitis in human medicine 
was based on histology since the etiology of the disease was largely unknown.  A 
distinction was made between a milder form of the disease, i.e. chronic persistent 
hepatitis, and variants with more severe disease activity, i.e. chronic active hepatitis (De 
Groote et al. 1968). Because chronic hepatitis in Dobermans histologically resembles 
human chronic active hepatitis, the name was also used for Dobermans.   
 
In human medicine today, the classification of chronic hepatitis is based on different 
etiological factors (Ludwig 1993). The terms ‘’chronic persistent hepatitis’’ and 
‘’chronic active hepatitis’’ have thus been replaced with ‘’chronic hepatitis’’. Likewise, 
for Dobermans, the term ‘’chronic active hepatitis’’ has been replaced with ‘’chronic 
hepatitis’’ (Zawie 1986, Center 1996b). Other commonly used names for hepatitis in 
Dobermans are ‘’copper-associated hepatitis’’ and ‘’Doberman hepatitis’’ (DH) (Hardy 
1986, King 1990). The emphesis in copper-associated hepatitis is on the typical Cu 
accumulations in the liver, while the term DH is used to stress that the disease in 
Dobermans differs from chronic hepatitis in other breeds. 
 
Several features are typical of DH. One of these is the aggressive nature of the disease. 
After the clinical signs of liver failure become obvious, the dog’s condition will 
deteriorate rapidlyvery fast (Meyer et al. 1980, Fiorito 1985, Rothuizen and Meyer 
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2000). Unfortunately, these clinical signs are usually not detectable until the liver has 
already been severely damaged. Another typical feature of DH is its poor response to 
treatment. The most commonly used medication is corticosteroids, with an  
immunosuppressive dosage to reduce the inflammatory process in the liver. However, 
corticosteroids, when started at the onset of  clinical signs, only temporarily improve the 
dog’s condition (Crawford et al. 1985, van den Ingh et al. 1988, Strombeck et al. 1988). 
This is in contrast to the treatment of chronic hepatitis in other breeds, where results are 
more favorable (Rothuizen 1997). A third typical feature of DH is that most of the dogs 
affected are female. The reason for this is unknown.   
 
Clinical signs usually appear at the age of 3-6 years. The youngest Doberman reported 
to suffer from DH was 1.5 years, and the oldest 11 years (Crawford et al. 1985, 
Fuenealbe et al. 1997). Clinical symptoms are not pathognomonic of DH. The most 
common signs are polydipsia and polyuria, anorexia, weight loss, and lethargy. Other 
signs include vomiting and diarrhea (Crawford et al. 1985, van den Ingh et al. 1988, 
Cornelius 1989a). 
 
Although the exact pathophysiological connection between chronic hepatitis and 
gastrointestinal problems has not been elucidated, chronic hepatitis is known to cause 
gastrointestinal symptoms (Kamath et al 2000). This is particularly evident when the 
patient is on corticosteroid treatment (Center 1996a). Icterus in DH manifests with 
discoloration of the sclera, mucous membranes, and urine, and in the advanced stages, 
also of the skin. Since the liver has a central role in blood coagulation, blood may be 
present in the stool, and bleeding can be associated with obtaining liver samples or with 
other surgical procedures in the advanced stages of DH.  In the later stages of the 
disease, ascitic fluid accumulates in the abdomen, and hepatic encephalopathy with 
altered mental status, including stupor, may be observed (Doige and Lester 1981, 
Rothuizen 1997).  
 
The etiology and pathogenesis of DH remains unknown, and studies on histological 
lesions in the subclinical stage of the disease are scarce. Most published cases were 
diagnosed when inflammation of the liver had already caused obvious damage to the 
parenchymal cells. Identifying affected individuals as early as possible is paramount. In 
the early stages of the disease, tissue destruction has just begun and the activated 
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immune system has not yet altered the original cell composition of the inflammatory 
cells. 
 
While Dobermans are known to be particularly susceptible to chronic hepatitis,  the 
prevalence of the disease in this breed has not been well established. In one study, the 
occurrence of  chronic hepatitis in Dobermans (2%) was considerably higher than in 
other breeds (0.12%) (Johnson et al. 1982). However, a survey of 106 healthy 
Dobermans (age 3 years) evaluating subclinical cases of DH reported a prevalence of  
21% (Mandigers et al. 2000). These high prevalences of chronic hepatitis in Dobermans 
suggest a genetic pre-disposition (Johnson et al. 1982, Thornburg et al. 1984, Hardy 
1985).  
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5.  REVIEW OF THE LITERATURE 
   
5.1.  Definition of chronic hepatitis  
 
In humans, an accurate diagnosis of chronic hepatitis requires a period of at least six 
months for both clinical and laboratory examination to indicate inflammation and death 
of liver cells (Hassi 1986, Desmet et al. 1994). Histologically, chronic hepatitis causes 
ongoing injury to liver cells, which is characterized by mononuclear inflammation in the 
portal and lobular areas with differing degrees of piecemeal necrosis that disrupts the 
limiting plate surrounding the portal area. Parenchymal inflammation varies. Bridging 
necrosis arises from portal to portal, portal to central, or central to central areas. For 
dogs, chronicity is generally defined as persistently abnormal liver tests and specimens 
over 4-6 months (Sarli 1992). 
  
5.2.  Laboratory tests to diagnose chronic hepatitis 
 
Signs of chronic hepatitis are not pathognomonic of liver dysfunction. Therefore, 
biochemical tests are used to establish the presence of liver tissue damage. Several 
laboratory tests are available, but measurement of serum liver enzymes is the most 
common indicator of hepatocellular damage. Serum liver enzyme tests, based on 
measurement of cellular contents that have been released into the circulation, can be 
divided into those reflecting hepatocellular injury and those indicating increased 
enzyme production (Meyer et al. 1992).  
  
5.2.1.  Alanine aminotransferase (ALT) 
Alanine aminotransferase (ALT) is considered to be the most specific liver enzyme in 
dogs. In addition to its physiological functions as an enzyme, ALT is useful for 
diagnosing disorders of the liver. It is a soluble cytoplasmic enzyme that is easily 
released through the cell membrane even when hepatocytes appear microscopically 
intact (Bush 1991, Center 1997). ALT can also be found in the heart, kidneys, and 
muscles. However, its concentrations in hepatocytes are several times higher than in 
other tissues (Center 1996c). Increased serum concentrations of ALT are therefore a 
good indicator that hepatocytes are somehow affected. The serum half-life of ALT in 
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dogs is approximately 48 hours (Richter 1996). However, increased production and 
release by viable and regenerating hepatocytes may contribute to changes in the serum 
ALT concentration. Elevated ALT values will not return to the normal range in just a 
few days. Moreover, elevated ALT values do not discriminate between the primary and 
secondary reasons for altered hepatocytes (Twedt 1998b). 
 
5.2.2.  Alkaline phosphatase (AP) 
Alkaline phosphatase (AP) is commonly used, usually in combination with ALT, to 
detect liver diseases in dogs. AP is a membrane-bound enzyme that is primarily located 
on the bile canalicular membrane of hepatocytes and the luminal surface of biliary 
epithelial cells (Leveille-Webster 2000). Elevated AP levels are the result of increased 
synthesis of the enzyme and are not due to the leakage of the enzyme from the cells, as 
described for ALT (Bush 1991, Meyer 1996). Several isoenzymes of AP can be found 
in the liver, kidney, intestine, bone, and placenta. The half-lives of isoenzymes for the 
kidney, intestine, and placenta are less than 10 minutes, and therefore, they are not 
clinically significant (Sevelius and Andersson 1995). In dogs, AP levels will increase 
after induction by glucocorticoids and anticonvulsants (Bush 1991, Cornelius 1997). In 
an adult dog’s serum, AP originates from the liver, is corticosteroid- or epileptic drug-
induced, or is the result of a pathologic bone condition. In growing dogs, AP is 
associated with increased osteoblastic activity (Leveille-Webster 2000). 
 
5.2.3.  Total bilirubin   
Serum bilirubin concentration is used to detect liver failure in addition to liver enzymes. 
Bilirubin is an end-product of heme metabolism. Approximately 80% of the bilirubin 
produced by a normal dog is derived from the removal of aged erythrocytes from the 
circulation by macrophages. Degradation of heme from other sources, including 
myoglobin, cytochromes, peroxidase, and catalase, accounts for the remaining bilirubin 
production (Bush 1991, Leveille-Webster 2000). In the plasma, bilirubin is in an 
unconjugated form and is carried to hepatocytes bound to albumin. Unconjugated 
bilirubin is water-insoluble and therefore must be conjugated to glucuronic acid in 
hepatocytes before being excreted into bile canaliculi. Conjugated bilirubin is poorly 
absorbed from the small intestine. In the large intestine, it is changed to urobilinogen by 
enzymes and is mainly secreted in the feces. Only a small portion is reabsorbed to the 
portal blood reaching the liver and another small portion to the systemic circulation to 
 18 
 
be excreted by the kidneys (Bush 1991, Leveille-Webster 2000). The measurement of 
total bilirubin includes both unconjugated and conjugated forms. The balance between 
bilirubin production from the hemoglobin and excretion from the bile duct is 
meintained under normal conditions. Hyperbilirubinemia then jaundice occur when 
this balance is upset due to increased breakdown of erythrocytes, impaired uptake of 
bilirubin to hepatocytes, or impaired release of bilirubin from hepatocytes to the 
canaliculus (Richter 1996, Kaneko et al. 1997). An increase in total bilirubin results in a 
yellow color in plasma when it is greater than 1 mg/dL (or 17.1 umol/L) and in other 
tissues at concentrations exeeding 2 -3 mg/dL (or 34.2 – 51.3 umol/L) (Meyer et al. 
1992).  
 
5.2.4.  ALT, AP, and total bilirubin in Doberman hepatitis (DH)    
ALT, AP, and total bilirubin serum concentrations were gathered from different 
research publications of DH. Only those reports were included where precise numerical 
values were available and the reference values of the laboratory were mentioned. 
Several articles fullfilled these criterions (Meyer et al. 1980, Doige and Lester 1981, 
Johnson et al. 1982, Thornburg et al 1983, Thornburg et al. 1984, Crawford et al. 1985, 
van den Ingh et al. 1988, Thornburg 1988, Cornelius 1989, Röcken et al. 1991, 
Fuentealba et al. 1997), providing a total of 91 blood samples from 61 Dobermans with 
DH.  
 
ALT values had been measured in all blood samples. Seventeen ALT values from eight 
dogs with subclinical hepatitis were reported in five different articles (Johnson et al. 
1982, Crawford et al. 1985, Thornburg 1988, Röcken et al. 1991, Fuentealba et al. 
1997); the serum ALT values were all abnormal, being 1.7-24.6 times higher than the 
normal upper value. In the remaining 74 blood samples  taken from Dobermans with 
clinical signs of liver failure, the ALT value was abnormal in 71 samples, ranging from 
1.6- to 58-fold the normal upper value. In the clinical stage of disease, ALT values of 
three of 74 blood samples (0.04 %), were within the normal range.   
 
AP values had been determined for 88 blood samples from 60 Dobermans with chronic 
hepatitis. Seventeen samples, as reported in five different articles, had been taken in the 
subclinical stage from eight Dobermans (Johnson et al. 1982, Crawford et al. 1985, 
Thornburg 1988, Röcken et al. 1991, Fuentealba et al. 1997); AP values ranged from 
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0.7- to 19.4-fold the normal upper value, being normal in one sample. In the clinical 
stage, the AP value measured from 71 blood samples was 0.7-75 times higher than the 
normal upper value.   
 
Total bilirubin value had been analyzed for 62 blood samples from 49 Dobermans with 
chronic hepatitis. In four studies, seven samples were measured from five Dobermans in 
the subclinical stage of the disease. The total bilirubin values were all in the normal 
range (Johnson et al. 1982, Crawford et al. 1985, Thornburg 1988, Fuentealba et al. 
1997). The remaining 55 blood samples were taken when dogs had clinical signs of 
liver failure. In this stage, total bilirubin was 0.3- to 51-fold the normal upper 
value,except for five samples in which it remained normal. 
 
5.3.  Histological findings in DH   
 
5.3.1.  Interpretation of the histological findings in liver samples   
In veterinary medicine, the two accepted models for histological evaluation of the liver 
are the classic lobule model and the acinar unit model (Meyer 1994). Based on these 
models, the location of different histological lesions can be recorded.  
 
In the classic lobule model, the lobule is the structural unit of the liver and it is rather 
easy to observe. A lobule is roughly hexagonal in shape and is composed of stacks of 
anastomosing plates of hepatic cells separated by the anastomosing system of sinusoids 
that perfuse the cells with the mixed portal and arterial blood. The central vein, into 
which the sinusoids drain, is located in the center of the lobule. The portal areas are at 
the angles of the hexagon (Maclachlan and Cullen 1995). 
 
In the acinar unit model, the acinus is a unit that is of more relevance to hepatic function 
because it is oriented around the afferent vascular system. However, the acinus is 
difficult to visualize because the zone has no sharp boundaries. The acinus consists of a 
roughly ellipsoidal mass of hepatocytes aligned around the hepatic arterioles and portal 
venules as they anastomose into sinusoids. The axis of the acinus is defined by the 
terminal branches of the portal triad that lie along the border between two classic 
lobules.  The hepatocytes in the acinus are divided into zones corresponding to the 
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distance from the arterial blood supply (Maclachlan and Cullen 1995). Hepatocytes 
closest to the arterioles (zone 1) are oxygenated best, while those farthest from the 
arterioles (zone 3) have the poorest supply of oxygen.   
 
In human medicine, liver specimens undergoing analysis for chronic hepatitis are also 
evaluated with the models described above. In addition, liver samples are analyzed for 
the severity of the necroinflammatory process (grade) and the extent of fibrosis (stage) 
(Hubscher 1998, Jevon 2001). While several systems are available, the Knodell 
histology activity index (HAI) was the first system developed and is today widely 
regarded as the golden standard (Knodell et al. 1981). In this system, four individual 
components (periportal necrosis +/- bridging necrosis, intralobular degeneration and 
focal necrosis, portal inflammation, and fibrosis) are analyzed. The degree of lesions in 
each component is scored, and the numerical value of the components is summed to 
produce an overall activity index (the HAI). Other grading and stating systems have 
subsequently been developed (Scheuer 1991, Ishak et al. 1995, Brunt 2000, Jevon 
2001). These systems provide a systematic means of comparing pre- and post-therapy 
biopsies and can therefore be used to evaluate disease progression and response to 
therapeutic intervention. With these systems, the severity of inflammation and the 
degree of fibrosis in liver tissue can be objectively described (Desmet et al. 1994, Jevon 
2001).   
 
5.3.2.  Histopathology of  DH   
Histological findings in chronic hepatitis have been presented in numerous reports on 
DH (Meyer et al. 1980, Doige and Lester 1981, Johnson et al. 1982, Thornburgh et al. 
1984, Crawford et al. 1985, Fiorito 1985, van den Ingh et al 1988, Thornburg 1988, 
Cornelius 1989, Fuenteable et al. 1997, Thornburg 1998). These are mainly cases with 
advanced liver destruction that also show clinical signs of liver failure. In the majority 
of these, the cellular infiltration consisted of lymphocytes and pigment-filled 
macrophages. Neutrophils and plasma cells were also found but were few in number. In 
the parenchymal area, especially in severe cases, the parenchyma was clearly distorted.  
The inflammation varied from mild to severe.  Inflammatory cell infiltration was 
virtually always recorded in the portal areas. In some cases, the limiting plates were 
intact, but usually piecemeal necrosis characterized by the erosion of the limiting plate 
was found. The portal areas were often expanded by a loose fibroplasia. Collagen and 
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reticular fibers extended into the lobulus. These fibers distorted the parenchyma, 
producing pseudolobulus of various sizes. The inflammatory cells were associated with 
connective tissue. Bile duct hyperplasia was commonly seen. Cholestasis was noted as 
bile plugs in canaliculus and depris filled-macrophages.  
 
The findings in one research article differed from other published observations 
(Thornburgh 1998). In this study, the first histological findings were observed in zone 3, 
around central veins and adjacent hepatocytes. An inflammation composed of 
lymphocytes, plasma cells, and macrophages in the walls of hepatic veins and loss of 
surrounding hepatocytes was seen. All cases featured acidophilic cells in zone 3, with  
the number of these cells increasing as the disease became more severe. For advanced 
cases of liver failure, inflammation in zone 3 and in the portal area was obvious, and 
scar tissue radiated from central veins towards the adjacent acinus. Cholestasis was 
observed in two of the 36 liver samples. No granules were detected in macrophages by  
special staining.   
 
Immunohistochemistry techniques have been used in two studies (Thornburgh 1998, 
Boisclair et al. 2001). In both of these studies, stainings were performed using paraffin-
embedded tissue in order to analyze the composition of lymphocytes. In the first study 
(Thornburgh 1998), T-cells were demonstrated using rabbit-origin polyclonal human 
CD3 antibody. B-cells and plasma cells were visualized by polyclonal rabbit-origin IgG 
antibody. The antibody for B-cells and plasma cells recognizes the Fc fragment of 
canine IgG.  CD3+ T-lymphocytes were observed in portal tracts and walls of the 
hepatic veins, but the number of T-cells was few. Anti-IgG antibody reacted only with 
plasma cells. These cells were also few in number and were seen around hepatic veins 
and portal tracks. 
  
In the second study (Boisclair et al 2001), lymphocyte compositions were evaluated 
using antibodies against CD3, which  detected T-cells, and antibodies against alpha and 
kappa light chains, which  detected B-cells. In the portal area, most of the lymphocytes 
were CD3+ lymphocytes. Also in the centolobular area CD3+ lymphocytes were the 
most abundant. Intralobular kappa and lamda chain-positive cells were not evaluated 
because of difficulties in differentiating between intrasinusoidal and intralobular cells. 
In most cases, more kappa chain-positive cells than lambda chain-positive cells were 
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present. A significant correlation was found between necrosis and the number of CD3+ 
lymphocytes and lambda and kappa chain-positive cells in the portal and lobular areas. 
 
5.4.  Classification of chronic hepatitis in man based on the etiology 
  
The response of the liver to injury caused by a variety of etiologic agents results in 
similar microscopic patterns, making it difficult to distinguish specific disease entities. 
However, after the diagnosis of chronic hepatitis has been made, a causative agent 
should be sought to ensure effective treatment.  
 
In human medicine, the etiology of chronic hepatitis is divided into infectious agents, 
metabolic disorders, toxins and drugs, and autoimmune diseases. These divisions are 
based on the correlations between clinical history, serological studies, and biopsy 
findings. Sometimes the etiology of chronic hepatitis cannot be determined because of 
the lack of serological markers for virus or autoimmune hepatitis and the absence of 
information about any drug. In these cases, the diagnosis made is idiopathic chronic 
hepatitis (Desmet et al. 1994, Jevon 2001).   
 
5.4.1.  Infection     
In humans, viruses, including hepatitis B and C (HBV, HCV) are the main etiological 
factor causing chronic hepatitis (Walsh and Alexander 2001). HBV is a DNA virus in 
which the major modes of transmission are prenatal, sexual, via blood products, and via 
contaminated needles in intravenous drug users (Lau et al. 1997, Walsh and Alexander 
2001). Of adults, 90% infected with HBV recover completely because of an effective 
immune system. A child whose immune system is not fully developed cannot eliminate 
the virus but instead will be chronically infected (Lau et al. 1997, Huang and Lok 
2003). The virus replicates within infected hepatocytes, causing the liver cell to make 
copies of HBV DNA. After HBV replication, hepatocytes secrete hepatitis B antigens 
and release intact virions which contain HBV DNA into the bloodstream. These viral 
copies can infect other liver cells, thus replicating effectively (Walsh and Alexander 
2001). The cells of the immune system recognize HBV-infected cells and induce them 
to undergo apoptosis. In addition to the killing of infected hepatocytes, activated T-cells 
secrete interferon-gamma (IFN-g), which interferes with the life cycle of the pathogen. 
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In chronic hepatitis B, the immune system is not capable of terminating the infection but 
progressively destroys some of the infected hepatocytes, leading to cirrhosis (Lau et al. 
1997). The diagnosis of HBV infection is based on detection of HBV antigen, 
antibodies against HBV, or HBV DNA in the patient’s serum (Walsh and Alexander 
2001). 
 
At present, HCV infection is the leading cause of chronic liver disease worldwide. 
(Verbaan et al. 1998, Busch 2001). HCV is a small RNA virus that is transmitted 
primarily through contaminated blood and less effectively by human body secretions. 
Vertical transmission can also occur (Busch 2001, Walsh and Alexander 2001). The 
characteristic feature of HCV infection is its high rate of viral persistence and its ability 
to progress silently to chronic liver disease. In contrast to HBV, where the virus is 
eliminated in up to 80% of patients, HCV infection almost invariably progresses to 
chronic hepatitis (Busch 2001). The mechanisms of persistence, replication, and cellular 
injury by HCV are not, however, well characterized (Marrogi et al. 1995, Wejstål 1995). 
Persistence appears to arise from the ability of the virus to undergo a high rate of 
mutation, resulting in a series of immunologically distinct variants that allow the virus 
to escape recognition by the immune system (Pouti et al. 1997). Chronic hepatitis C is 
diagnosed when serum transaminases are persistently elevated in the presence of HCV 
antibodies.   
   
5.4.2.  Metabolic disorders   
Inherited metabolic disorders can also manifest as chronic hepatitis in humans. The 
most common of these conditions are Wilson's disease and alpha-1 antitrypsin (α-1-A) 
deficiency.  
 
Wilson's disease is an autosomally recessive inherited disease of copper metabolism. 
The mutation results in dysfunction in the gene (APT7B) encoding copper (Cu) 
transporter ATPase (Schilsky 2002, Subramanian et al. 2002). APTase transports Cu 
from one side of the hepatocytic membrane to the other. A defect in this protein leads to 
impaired biliary excretion of Cu and its retention by hepatocytes. When the hepatic 
storage capacity of Cu is exceeded, parenchymal inflammation followed by cell death 
ensues, with Cu release into the plasma, causing hemolysis. Copper also accumulates in 
the brain, cornea, and kidneys (Brewer 2000). The diagnosis of Wilson's disease is 
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made when decreased serum ceruloplasmin, increased urinary copper content, and 
elevated hepatic copper concentration are observed. Kayser-Fleischer rings, i.e. rusty 
brown rings around the cornea of the eye, are also diagnostic of Wilson's disease 
(Loudianos et al. 2000, Schilsky 2002). 
  
α-1-A is the predominant genetic cause of liver disease in children and the most 
common genetic disorder for which children undergo liver transplantation (Perlmutter 
1996). The α-1-A molecule is a serum glycoprotein that is predominantly expressed by 
hepatocytes but is also synthesized by a number of extrahepatic cell types and tissues. It 
is an acute phase protein and its concentration in plasma increases during host response 
to tissue  injury or inflammation. Its major physiological function is inhibition of the 
destructive neutrophilic protease elastase (Hussain et al. 1991, Lomas 1996). Several 
phenotypes of α-1-A protein exist. However, from a pathological perspective, only one 
type, PIZZ, is important.. In this phenotype, both gene alleles are mutated. This mutated 
α-1-A molecule is responsible for an alteration in the folding of the α-1-A protein, 
resulting in its retention in the endoplasmic reticulum (ER) of hepatocytes (Qu et al. 
1997). The hepatocytic accumulation causes the serum α-1-A concentration to decrease 
below physiological level. The consequence of this in most affected individuals is 
progressive lung disease since an insufficient level of α-1-A cannot prevent the 
neutrophilic enzyme from destroying the collagen of the lung (Crystal 1990). In contrast 
to the pathogenesis of lung in α-1-A deficiency, no evidence exists that liver injury is 
due to a deficiency in elastase inhibitory capacity. Most evidence favors the concept that 
the accumulation of α-1-A in the ER is directly related to liver cell injury (Lomas et al. 
1992, Perlmutter 1996, Qu et al. 1997). Affected individuals may be diagnosed based on 
detection of periodic acid-Schiff (PAS)-positive, diastase-resistant globules in the 
hepatocytic ER. However, in cases where these globules are absent, identification of the 
α-1-A phenotype is important in diagnosis of the disease (Crystal 1990).   
 
5.4.3.  Drugs and toxins   
The liver is the major site of drug metabolism and is therefore a common target of 
adverse drug reactions (Beaune and Lecoeur 1997). Most drug-induced chronic hepatitis 
is idiosyncratic in nature (Pirmohamed et al. 1996, Uetrecht 1997, Castel 1998). An 
idiosyncratic reaction often has serious consequences, and it is impossible to predict 
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who will develop such a reaction. Idiosyncratic reactions are also dose-independent 
such that most individuals will have no adverse response to the drug at any dose while a 
few may have an exaggerated response to a very low dosage. Under normal conditions, 
most drugs undergo some degree of bioactivation without causing any harm. This is due 
to the metabolites being effectively detoxified. However, harmful chemically reactive 
metabolites are formed when inadequate detoxification occurs. This may be the result of 
a genetically determined deficiency of enzymes involved in detoxification or a 
disturbance caused by environmental factors such as infections, diet, or concomitant 
drug intake (Pirmohamed et al. 1996). The mechanisms involved in the pathogenesis of 
idiosyncratic drug reactions remain obscure. Harmful metabolites are speculated to 
cause a toxic insult on the cell either directly or indirectly by acting as a hapten and 
initiating an immune-mediated reaction (Castel 1998). No specific markers or tests for 
drug-induced liver injury are available. Therefore, the diagnosis is usually based on 
pharmacological history, the relationship between drug intake and the onset of clinical 
signs, and the exclusion of other etiological factors. In humans, a clinical diagnostic 
scale has been developed for evaluating drug-induced liver injuries (Vasco and Rui 
1997, Aithal et al. 2000).   
 
5.4.4.  Autoimmunity   
Autoimmune hepatitis is a disorder of unknown etiology in which progressive 
destruction of the hepatic parenchyma occurs. Females seem to be more susceptible, and 
often there is a family history of other disorders thought to have an autoimmune 
etiology (Al-Khalidi and Czaja 2001). A typical feature of autoimmune chronic 
hepatitis is a good response to corticosteroid therapy (Czaja 2002). Althouhg the 
pathophysiological mechanisms are not yet fully understood, evidence suggests that 
autoimmune hepatitis develops after genetically susceptible individuals have been 
exposed to an initiating factor, such as a hepatotropic viral infection or an idiosyncratic 
reaction to a drug or other hepatotoxin (Czaja 2002). The immune reaction may be 
related to defects in the immunological control of autoreactivity, with consequent loss 
of self-tolerance to liver auto-antigens (van den Berg 1998). As there are no 
morphological features that are pathognomonic of the condition to distinguish 
autoimmune chronic hepatitis from other forms of hepatitis, the diagnosis is based on 
laboratory results, after ruling out other causes of chronic hepatitis. Serologically, the 
disease is characterized by hypergammaglobulinemia with elevated levels of IgG and 
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high titers of a wide range of circulating auto-antibodies. The most common auto-
antibodies are ANA, SMA, and LKM-1 (Luxon 2003). In addition, no serological signs 
of viral infections are present. Other findings include elevated aminotransferase levels, 
normal serum α-1-A and ceruloplasmin concentrations, normal liver Cu content, and no 
recent use of known hepatotoxic drugs (van den Berg 1998, Al-Khalidi and Czaja 
2001).   
  
5.5.  Possible etiological factors of DH 
 
The etiology of DH is unknown partly due to the lack of specific serological tests for 
humans. Disease categorization is therefore not based on etiological factors, and DH is 
classified together with copper-associated hepatitis, breed-associated hepatitis, or 
hepatitis with familial predisposition (Johnson 1982, Hardy 1986, Dill-Mackey 1995, 
Sterczer et al. 2001).  
   
5.5.1.  Infection   
Infection as a cause of DH has been proposed, although the specific agent remains to be 
determined (Rothuizen 1997). To date, canine adenovirus 1 (CAV-1) is the best-
known viral cause of chronic hepatitis in dogs (Chouinard et al. 1998). This highly 
contagious virus is transmitted by contact with infected animals and contaminated 
fomites (Sherding 2000). Since an effective vaccination is available, the incidence of 
adenovirus-caused hepatitis is under control. Definitive diagnosis is based on increased 
antibody titers to CAV-1 and viral isolation from affected tissues (Sherding 2000). 
 
In addition to CAV-1-induced chronic hepatitis, asidophilic cell hepatitis is a distinct 
form of chronic hepatitis caused by a transmissible agent which is most probably a virus 
(Jarrett et al. 1987). This hepatitis could be transmitted to a healthy dog via the infected 
serum and liver homogenate of a euthanized dog. Asidophilic cell hepatitis is 
histologically characterized by acidophilic cells and only a small number of 
mononuclear cells.  
 
Leptospira is a potential agent of chronic hepatitis in Dobermans. This bacteria is 
spiral-haped and has several serotypes. Leptospira interrogans serovars 
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icterohemorhagiae and canicola previously were the most common leptospiras causing 
liver failure (Nielsen et al. 1991, Harkin and Gastrell 1996). However, other serovars, 
such as grippotyphosa, pomona, bratisvala, and australis, have replaced 
icterohemorhagiae and canicola partly because a vaccination against L. 
icterohemorhagigae and L. canicola is available decreasing their role as causative agents 
of liver failure (Bishop et al. 1979, Nielson et al. 1991, Brown 1996, Harkin and 
Gastrell 1996, Adamus et al. 1997). Animals become infected through contact with 
contaminated urine, water, or soil. The bacteria enter the body through the skin or 
mucous membranes. Our current understanding of the pathogenesis of leptospirosis is 
incomplete. During tissue invasion, there seems to be direct leptospiral cytotoxic effect 
on endothelial and hepatocytic membranes (Alves et al. 1992). The diagnosis depends 
on detecting the leptospira in clinical specimens and/or demonstrating an increase in 
antibody titers to one or more leptospiral serovars (Harkin and Gastrell 1996).  
 
5.5.2. Metabolic disorders   
Liver Cu content in a healthy dog does not exceed above 400 µg/mg dw (dry weight) 
(Rolfe and Twedt 1995, Twedt 1997). At this concentration, Cu is not histologically 
detected (Thornburg et al. 1985). Hepatitis is not however, apparent until Cu 
concentration exceeds 2000 µg/mg (Thornburg et al. 1990, Rolfe 2000).   
 
In Dobermans with chronic hepatitis, increased hepatic Cu levels have been widely 
observed (Doige and Lester 1981, Johnson et al. 1982, Thornburg et al. 1984, Crawford 
et al. 1985, Hardy 1986, van den Ingh et al. 1988, Cornelius 1989a). However, the role 
of Cu in the disease is contradictory. The most common theory is that increased Cu 
concentration is secondary to cholestasis (Johnson et al. 1982, van den Ingh et al. 1988, 
Cornelius 1989a). This suggestion is based on histological evidence of biliary stasis, 
characterized by the accumulation of biliary pigments in hepatocytes and plugs in ducts. 
Dogs almost invariable have concomitant hyperbilirubinemia. Histologically, Cu is 
located in the periportal area or in the lobular periphery, providing evidence of the 
cholestatic nature of Cu accumulation (Meyer et al. 1980, Doige and Lester 1981, 
Johnson et al. 1982, Crawford et al. 1985, van den Ingh et al. 1988, Cornelius 1989a).  
  
Based on a study of two Dobermans with subacute hepatitis, Dobermans, similar to 
Bedlington Terriers, were proposed to be affected with a hereditary defect in Cu 
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metabolism (Thornburgh et al. 1984). While livers in this study histologically normal, 
abundant Cu-positive granules were present in the centrolobular hepatocytes. 
 
Other studies suggest that Cu is neither the cause nor the effect of chronic hepatitis in 
Dobermans but is incidental, also suggesting that hepatic Cu concentration can normally 
be above 400 µg/mg dw without predisposing to chronic liver disease (Thornburgh et al. 
1990, Thornburgh 1998). No evidence has been focused that Dobermans, or other 
breeds, accumulate Cu secondary to chronic cholestasis. This is unlike in human 
patients with chronic biliary disease, such as primary biliary cirrhosis, in which it 
usually takes years for Cu to accumulate  in hepatocytes. In this study (Thornburgh 
1998), comprising 35 Dobermans with chronic hepatitis, 30 dogs had elevated hepatic 
copper concentrations and five dogs had normal levels. In all 30 samples in which 
increased Cu was present in rhodanine staining, the Cu-laden hepatocytes were 
restricted to zone 3 of the acinus, adjacent to the hepatic vein branch, or adjacent to 
zone 3 scar tissue.   
 
In the Netherlands, 3-year-old Dobermans were evaluated for subclinical hepatitis 
(Mandigers et al. 2000). Liver samples were analyzed for inflammation as well as 
increased Cu content. Results indicated that most Dobermans with subclinical hepatitis 
also had elevated liver Cu content.  
  
α-1-A was evaluated in 13 dogs with chronic hepatitis, including three Dobermans  
(Sevelius et al. 1994). The α-1-A phenotype was divided into the following three 
categories: fast (F), intermediate (I), and slow (S). These appeared in either a 
homozygous (FF, II, SS) or a heterozygous (FI, FS, IS) form. In dogs considered to 
have true α-1-A accumulation, the phenotype was either II or FI. Immunohistochemical 
examination revealed three staining patterns, and globular staining indicated the true 
accumulation in hepatocytes. Granular and diffuse staining are not regarded as an 
aggregation of α-1-A but as a secondary phenomena to inflammation. In all three 
Dobermans, α-1-A presented as diffuse staining in the periportal and centrolobular 
areas. The phenotype was homozygous fast (FF). The serum concentration of α-1-A in 
these three dogs was elevated compared twith control dogs.  
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5.5.3.  Drugs and toxins   
Drugs can also cause chronic hepatitis in Dobermans. Anticonvulsants, primidone, 
phenytoin, and phenobarbital have been shown to have hepatotoxic effects, especially in 
long-term treatment of dogs (Bunch et al. 1982). Diethylcarbamazine with 
oxibendadazole, drugs used for heartworm prophylaxis, are also known to cause 
hepatitis in Dobermans (Vaden et al. 1988).  
 
5.5.4. Autoimmunity   
Cell destruction in DH may be caused by a malfunctioning autoimmune system. 
Evidence for this hypothesis is, however, lacking (Rothuizen.et al. 1998). The 
autoimmune background in DH has been evaluated mainly by measuring autoantibodies 
in the serum of affected dogs (Crawford et al. 1985, Cornelius 1989a, Andersson et al. 
1992, Sevelius et al. 1993, Weiss et al. 1995). Although the pathogenic role of 
autoantibodies in autoimmune disorders is unclear, they serve as markers for 
autoimmune diseases and are widely used as a diagnostic tool. In humans, antinuclear 
antibodies (ANA) are detected in cases of autoimmune hepatitis type I (Luxon 2003). 
Altogether, 15 different Dobermans with chronic hepatitis were analyzed antibodies for 
ANA (Crawford et al. 1985, Cornelius 1989a, Sevelius et al. 1993). In 4 of 15 cases 
(27%), elevated antibody titers against nuclear antigens were present. In humans, 
antibodies against smooth muscle antigens (SMA) are also found in the majority of 
individuals with autoimmune hepatitis. Antibodies against mitochondrial antigens are 
found in 98% of cases of primary biliary cirrhosis (Kaplan 1993, Galperin and 
Gershwin 1996). Sevelius et al. (1993) evaluated the serum samples of Dobermans with 
chronic hepatitis for antibodies against SMA and mitochondrial antigens. Neither of 
these autoantibodies was found. Antibodies against liver-specific antigens were 
evaluated in two studies. Sevelius et al. (1993) measured liver membrane autoantibodies 
(LMA) in the serum of three Dobermans with chronic hepatitis but found no antibodies. 
In a second study, antibodies against liver membrane protein (LMP) were evaluated in 
the serum of four Dobermans with chronic hepatitis. In two of these four Dobermans, 
the anti-LMP titer was four times higher than in controls. The other two, with anti-LMP 
titers equal to those in controls were receiving corticosteroid treatment (Weiss et al. 
1995).   
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5.6.  Major histocompatibility complex (MHC) class II  expression 
 
MHC molecules are special inherited proteins expressed on the surface of an animal's 
cells. As tissue histocompatibility proteins, they present antigenic peptides to T-
lymphocytes. They are composed of two polypeptides, an alpha and a beta subunit, 
which form a groove where the antigen is located (Rask et al. 1991, Day 1999). MHC 
class I antigens are more ubiquitously distributed in all cells than MHC class II 
antigens, which are mainly located in so-called professional antigen-presenting cells 
(APCs) (Mellins 1992, Tizard 1996).  MHC class II molecules have two major 
functions. In the thymus, they are expressed on thymocytes, where they present 
different autoantigens to developing T-cells. In positive selection, only T-cells that can 
react with MHC class II molecules survive. Afterwards, in negative selection, those T-
cells reacting with auto-antigens presented by MHC class II molecules are destroyed. 
Through positive and negative selection, over 90% of bone-derived T-cells are 
prevented from entering the bloodstream (Janeway et al. 1999a).   
 
The second function of MHC class II is to present processed antigens to CD4+ T-cells 
(Janeway et al. 1999b). Outside the thymus, MHC class II molecules are expressed 
exclusively on very few cell surfaces. These cells consist of macrophages, dendritic 
cells, and B cells, and are collectively refered to as APCs (Mellins 1992, Tizard 1996).  
MHC proteins are synthesized and integrated with an antigen in the cytoplasm of an 
APC. The stable MHC antigen complex is then transported to the cell membrane and 
presented to T-cell receptors (TCRs). Helper T-cells have a molecule called CD4, which 
binds to MHC II. Moreover, an antigen located in the groove of MHC class II on the 
cell surface of APCs is bound by highly specific TCRs, also expressed on the surface of 
helper T-cells (Janeway et al. 1999b). These interactions, with the help of costimulatory 
factors, are necessary for the activation of helper T-cells. After activation, helper T-cells 
initiate the release of cytokines that regulate other processes associated with immune 
responses (Day 1999).  
 
5.6.1.  MHC class II in diseases  
Under normal conditions, the body has a tolerance to its own antigens. This tolerance is 
mainly due to the deletion of autoreactive T-cells in the thymus before their entry into 
 31 
 
the bloodstream. This ensures that T-cells, which react with the body’s own antigens, 
are destroyed (Janeway et al. 1999a). However, this mechanism is not perfect, and as a 
result, all living being have autoreactive cells in their bodies. Autoimmunity is a 
phenomenon where the body’s own immune system has failed to arrest these 
autoreactive cells. Alternatively, autoantigens which the immune system has not 
encountered before may become exposed. Autoimmune response develops because 
there is no tolerance to these antigens (Janeway et al. 1999c).   
 
A genetic association exists between certain autoimmune diseases and the expression of 
specific MHC class II molecules (Nepon 1991, Rask et al. 1991, McDevitt 1998). This 
association is hypotherized to arise from an altered thymic selection. Autoreactive T-
cells may escape selection in the thymus as a consequence of the poor peptide-binding 
properties of disease-associated MHC class II molecules (Ridgway and Fathman 1998). 
Among other possibilities, disease-predisposing MHC class II molecules may 
preferentially bind and present to pathogenic peptides.   
 
In addition to the genetic association between certain MHC class II molecules and 
autoimmune diseases, abnormal MHC class II expression in non APCs is also a 
common finding in several autoimmune diseases (Selby et al. 1983, Ballardini et al. 
1984, Lindahl et al. 1985, Altomonte et al. 1999). It is hypothesized that aberrant MHC 
class II on non immune cells allows cells to become antigen-presenting cells, to present 
antigens to T-cells leading to T-cell activation, and the development of autoimmune 
disease or local immune damage to tissues. 
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6.  AIMS OF THE STUDY  
 
A framework was sought to facilitate diagnosis of subclinical Doberman hepatitis (DH) 
and evaluation of the etiopathogenesis of the disease. The thesis was divided into four 
parts with specific goals as follows:   
 
Study I : - to determine which enzyme, ALT or AP, is the most  practical and reliable 
serum parameter for screening Dobermans with subclinical hepatitis. 
   
- to evaluate which serum parameters are the best indicators showing that 
the disease is progressing from the subclinical to clinical stage.  
 
Study II: - to describe histopathological changes in the liver in subclinical DH. 
 
- to compare histopathological changes between the subclinical and clinical 
stages of DH  
  
Study III: - to clarify the role of copper in DH based on biochemical, histological, and 
histochemical findings. Emphasis was on subclinical DH, comparing the 
distribution of copper in the subclinical stage with that in the clinical stage.   
    
Study IV: - to evaluate MHC class II expression in hepatocytes in DH from etiological 
and pathophysiological perspectives 
 
- to evaluate the correlation of mononuclear inflammation with MHC class 
II expression in hepatocytes. 
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7.  MATERIALS AND METHODS 
Characteristics of the dogs in Studies I-IV are shown in Table 1.   
  
7.1.  Study material    
 
Study I: Subclinical hepatitis was evaluated in a population of 626 (425 female, 201 
male) randomly selected, clinically healthy Finnish Dobermans between 1987 and 1994.  
The age of these dogs ranged from 1.5 to 9.5 years. Blood samples were collected 
mostly at dog shows and breeding association meetings. In 55 dogs, ALT concentration 
was greater than three times the normal upper value. ALT value was rechecked and if it 
remained elevated, the owner was asked for permission to take a liver biopsy from their 
dog. Thus, a liver biopsy was performed for 23 dogs. Those Dobermans considered to 
have subclinical hepatitis based on histological findings of the liver were further studied 
through an ongoing evaluation of their clinical status and measurement of serum 
parameters, including ALT, AP, and total bilirubin. The serum biochemical data of dogs 
with subclinical hepatitis were then compared with serum parameters of 22 Dobermans 
with clinical signs of chronic hepatitis. These 22 Dobermans were composed of six dogs 
diagnosed in the subclinical stage but who had clinical signs of liver failure during 
follow-up and 16 dogs diagnosed while having clinical signs of DH. All the clinically 
affected dogs were euthanized, and the diagnosis of advanced DH was based on 
histological evaluation of postmortem liver samples.  
  
Study II: Histological changes observed during liver biopsy of 20 Dobermans with 
subclinical hepatitis were recorded. During follow-up eight of these dogs were 
euthanized for reasons other than DH; as follows: aggression (3), postoperative bleeding 
(1), thrombocytopenia (1), lung tumor (1), renal failure (1), and gastric ulcer (1). For 
five of eight, an autopsy was performed. Since these dogs showed no clinical signs of 
liver failure, they were considered to be in the subclinical phase. Six dogs within the 
remaining population of 12 Dobermans with subclinical hepatitis showed typical signs 
of liver failure and were euthanized. An autopsy liver specimen was obtained from four 
of these six dogs. Histological findings of Dobermans with subclinical hepatitis were 
compared with histological observation of autopsy samples of clinically affected 
Dobermans.   
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Study III: Only these dogs with DH were included for whom Cu could be analyzed 
quantitatively and qualitatively. The role of Cu in DH was evaluated based on results 
obtained from biopsies of 17 Dobermans with subclinical hepatitis and from autopsies 
of 23 Dobermans euthanized because of the disease. The control group consisted of 
postmortem liver specimens obtained from 12 Dobermans euthanized for reasons other 
than DH. Reasons for euthanasia were aggression (1), dilatation and torsion of the 
stomach (1), adenocarcinoma of the duodenum (2), unknown reason (3), changed family 
situation (4), and car accident (1). Histologically, none of these dogs had signs of 
hepatitis in the liver.    
  
Study IV: MHC class II expression in hepatocytes was studied in 18 biopsies of dogs in 
the subclinical stage of DH, in 6 autopsies of dogs suffering from DH and euthanized 
for reasons other than liver failure, in 14 autopsies of dogs suffering from DH and 
euthanized because of the end-stage of the disease, and in 6 control Dobermans. From 
10 of the dogs with DH, both biopsy and autopsy samples were available for analysis of 
MHC class II expression changes during disease progression. The liver samples of dogs 
in this study were embedded in paraffin within one week in order to avoid changes in 
antigens in the formalin.   
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Study Number of animals Sex  Signs of ALT Liver Copper in Immuno-
 Age, yrs (mean) liver value biopsy / rubeinic histology
  failure autopsy acid stain  
I 626 Dobermans 1 F 425, M 201 No
1.5 - 9.5  
21 Dobermans with sDH F 17,  M 4 No Incr 2 b pos
2 - 7  (3.8) 
22 Dobermans with cDH F 13, M 9 Yes Incr a pos
 2.5 - 10  (6)
II 18 Dobermans with sDH F 15, M 3 No Incr 2 b pos
 2 - 7 (4.1) 
5 Dobermans with sDH 3 F 4, M 1   No Incr a pos
4 - 7 (5.2)
4 Dobermans with cDH 4 F 4 Yes Incr a pos
2 - 9 (6.6)
2 Dobermans with F 1, M 1 No Incr 2 b1 neg
   suspected sDH 4 - 6 (5)
III 17 Dobermans with sDH F 13, M 4 No Incr 1 b pos 5
2 - 7.9 (4.4)
23 Dobermans with cDH F 15, M  8 Yes Incr a pos 5
2.9 - 10 (5.8)
12 control Dobermans F 8, M 4 No ND a pos 5
2 - 13 (5.6)
IV 18 Dobermans with sDH F 15, M 3 No Incr 1 b pos Yes 6
2.2 - 7.9
6 Dobermans with sDH 3 F 5, M 1 No Incr a pos Yes 6
4 - 7 (5.6)
14 Dobermans with cDH F 10, M 4 Yes Incr a pos Yes 6
3.5 - 10 (6.4)
6 control Dobermans F 3, M  3 No ND b  1 neg Yes 6
3.5 - 12 (6.4)
ALT = alanine aminotransferase sDH = subclinical Doberman hepatitis; cDH = clinical Doberman hepatitis; 
F = female; M = male; ND = not determined
a = autopsy; b = liver biopsy revealed mononuclear inflammation in parenchymal and portal areas; 
b1 = liver biopsy; revealed no mononuclear inflammation in parenchymal and portal areas 
1 randomly selected clinically healthy Dobermans; 2 ALT values exceeding the normal maximum by at least 
three times in two concequtive blood samples; 3 diagnosed in the subclinical stage of DH but euthanized   
for reasons other than DH; 4 diagnosed in the subclinical stage of DH and euthanized because of DH; 
5 quantitative copper analysis of the liver was available; 6 Major histocompatibility complex (MHC) class II 
detection using  anti MHC class II antibody
Table 1. Characteristics of animals in the different study groups.
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7.2.  Diagnostic methods  
 
7.2.1.  Biochemistry   
Alanine aminotranspherase (ALT), alkaline phosphatase (AP), and total bilirubin 
Serum ALT and AP levels were analyzed according to the recommendations of the 
Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical 
Physiology (1974). ALT and AP values were determined from patients both in the 
subclinical and in the clinical stages of DH. Serum bilirubin was determined by using 
the azo-bilirubin method (Michaelson 1961). Blood parameters (ALT, AP, total 
bilirubin) were compared between stages of DH to evaluate which serum parameters 
were best for indicating progression of the disease from the subclinical to the clinical 
stage. All samples were analyzed in the same laboratory.   
 
7.2.2.  Histology    
Liver biopsies were obtained via laparatomy by ligation from the left medial lobe of the 
liver. The autopsy samples were taken immediately after euthanasia to minimize any 
postmortem changes.  
  
Liver specimens were placed in 10% buffered formalin solution for fixation. After 
fixation, the samples were embedded in paraffin. All sections were stained with 
hematoxylin and eosin (HE) and rubeinic acid. Some of the samples were also stained 
with van Gieson (VG) for analysis of connective tissue, with Unna Pappenheim for 
evaluation of plasma cells (Study II), with Rhodanine for Cu examinations (Study III), 
and immunohistochemically with antibodies against MHC class II  antigens (Study IV).  
 
7.2.3.  Immunohistochemistry   
All samples were fixed in 10% unbuffered formalin and embedded in paraffin. Liver 
samples were sectioned and mounted on poly-l-lysine-coated slides for 
immunohistological staining (DAKO EnVisionTM+System, Peroxidase, HRP, 
Carpinteria, USA). The sections were first passed through graded xylene and alcohol 
solutions. The unmasking of antigens was performed by heating the sections in a 
microwave oven in 10 mM citrate buffer (pH 7.2) twice for seven minutes. Endogenous 
peroxidase was blocked by incubating the sections with 0.03% hydrogen peroxide for 
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five minutes. The slides were subsequently incubated with the primary anti-MHC class 
II antibody for 30 minutes (anti-human HLA-DR alpha chain MoAb at 1:25 dilution, 
clone TAL 1B5, DAKO). To demonstrate the presence of MHC class II antigens, a 
horseradish peroxidase (HRP)-labeled conjugated secondary antibody was used for 30 
minutes. The reactions were developed by the addition of 3,3'-diaminobenzidine 
chromogen solution (DAB), and the sections were counter-stained with Mayer's 
hematoxylin. The primary antibodies were diluted in bovine serum albumin (BSA) 
diluted in Tris Buffered Saline (TBS). The sections were washed three times in TBS 
between each incubation stage, and all incubations were performed at room 
temperature. Canine tonsils served as positive controls and negative controls consisted 
of specimens in which the primary antibody was replaced with BSA/TBS.  
  
7.2.4.  Quantitative analysis of liver copper content    
For quantitative hepatic Cu assay, liver samples were stored at –20ΟC, then dried at 
105ΟC overnight, weighed, and digested in 0.5 ml of concentrated HNO3. The digests 
were diluted to 3 ml with water, and Cu was determined by flame atomic absorption 
spectrometry. A Perkin Elmer 2100 spectrometer was used according to the 
manufacturer’s instructions.  
 
7.3.  Interpretation of histological findings in liver samples 
 
7.3.1.  Classic lobule model   
The liver sections were analyzed using the classic lobule model, where lobular area was 
defined as an area with a central vein in the midle and portal areas at the angles. The 
lobular area was studied as a different area in order to better localize findings in the 
liver section. The lobular area was divided into parenchymal, portal, and periportal 
regions where parenchyma refers to the lobular area excluding the portal and periportal 
areas. In Study II, the  term lobular area was replaced with lobule. In that study, lobule 
had been defined as an area with a portal region, a central vein, and parenchyma was 
divided into periportal and centrolobular regions. Bridging necrosis refered to the 
necrotic areas between the two portal regions, between the two central regions, and 
between the portal and central regions. In Study II, when evaluating the histological 
lesions in the subclinical and clinical stages of the disease, the bridging necrosis areas 
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were added to the piecemeal necrosis areas. In Studies III and IV, bridging necrosis 
areas were recorded separately for analysis.   
 
7.3.2.  Scoring and grading of histological lesions   
Histological findings were numerically recorded to enable statistical analysis of lesions 
in specific locations in different liver samples and comparison of severity of lesions in 
samples of the same dog obtained at different time intervals. In Study II, the grading of 
portal inflammation, periportal+- bridging necrosis, and fibrosis were modified from the 
system used by Knodell et al (1981). In the Knodell system, periportal +/- bridging 
necrosis was weighted more heavily than other parameters because it appears to be 
more relevant in determining the severity of chronic hepatitis. The grading system used 
here for inflammation in the parenchyma, portal expansion, and bile duct proliferation 
was created by the author (Table 2). In Study III, the grading criteria for inflammation 
were based on Table 2, where the intensity of mononuclear inflammation in the 
centrolobular area was analyzed as inflammation in the parenchymal area. In Study IV, 
the grading criteria for inflammation was also based on Table 2, but in this study the 
scores were 0, 1, 2, and 3, as opposed to 0, 1, 3, and 4 as in Studies II and III. In Study 
III, the intensity of the inflammatory reaction in the bridging necrosis area was graded 
as follows: 0=none, 1=mild (sprinkling of inflammatory cells in <35% of the bridging 
necrosis area), 3=moderate (increased inflammatory cells in 35-65% of the bridging 
necrosis area), 4=marked (dense packing of inflammatory cells in >65% of the bridging 
necrosis area). In Study IV, grading of the intensity of inflammatory reaction in the 
bridging necrosis area was the same as in Study III, except the scores were 0, 1, 2, and 
3.  
 
 
Table 2. Grading of histopathological findings for hepatitis in Dobermans. 
                    
Score Parenchymal   Portal  Periportal +/-  Portal  Bile-duct  Fibrosis 
  inflammation**   inflammation  bridging necrosis  expansion  proliferation    
                    
0 None   None    Nonea  None  Noned  None 
                    
1 Mild (sprinkling of small   Mild (sprinkling of inflam-  Mild piecemeal necrosis  Mild (<50% of portal  2-4 bile ducts / portal   Fibrous portal expansion 
  groups and/or  single    matory cells in <35% of  (limiting plate ruptured  tracts expanded. Bor-  area, on average    
  inflammatory cells in   portal tracts)  in some portal areas)  ders irregular and ex-       
  parenchymal area)         hibiting fibrous  spurs)       
                    
3 Moderate (inflammatory   Moderate (increased in-  Moderate piecemeal ne-  Moderate (>50% of por-  5-6 bile ducts/portal   Bridging fibrosis (portal- 
  cells in sinusoids are   flammatory cells in  crosis (<50% of the  tal tracts expanded.   area, on average  portal or portal-central 
  intermediate)    35-65% of portal  circumference of most  Borders irregular and     linkage) 
      tracts)  portal tracts involved)  exhibiting fibrous      
          spurs)       
                    
4 Marked (severe inflam-    Marked (dense packing  Marked piecemeal necro- Marked (portal tracts ex-  >6 bile ducts/portal   Cirrhosise 
  mation in parenchyma)   of inflammatory cells  sis (>50% of the circum-   panded severely and   area, on average    
      in >65% of portal  tracts)  ference of most portal  connective tissue trib-       
          tracts involved)  utaries from portal ar-       
            eas throughout the liver)       
                   
         Moderate piecemeal ne-          
         crosis plus bridging           
         necrosisb          
                    
        Marked piecemeal necro-         
         sis plus bridging necro-          
         sisb           
                    
         Multilobular necrosisc          
** Parenchyma is referred to as  lobular area excluding portal and periportal areas. 
a Limiting plate intact in every portal area. 
b Bridging defined as > two bridges in one liver specimen; no distinction made between portal-portal and portal-central linkage. 
c Two or more contiguous lobules with panlobular necrosis. 
d < 2 bile ducts / portal area, on average.  
e Loss of normal hepatic lobular architecture with fibrous septa separating and surrounding nodules.  
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7.3.3.  Cholestasis   
In Study III, cholestasis was histologically evaluated using HE stain. Cholestasis stands 
out microscopically as greenish-brown bile thrombi between the hepatocytes in the 
canaliculus and was detected with oil immersion (1000 x) magnification. The number of 
bile plugs was graded as 0 (no plugs/liver section), 1+ (1-10 plugs/liver section), and 2+ 
(>10 plugs/liver section).    
 
7.3.4.  Copper   
Copper-positive granules were evaluated in both rubeinic acid and rhodanine stains to 
compare how effective these two stains are in detecting Cu granules. In addition, the 
numbers of Cu-positive granules with the rhodanine stain were classified to enable 
evaluation of the relationship between location of mononuclear inflammatory reaction 
and associated Cu accumulation. Rhodanine stain was used because the counterstain 
allows for the evaluation of the location of Cu-positive granules in liver samples. The 
number of Cu-positive granules with the rhodanine stain was classified as follows: 
0=none, 1=solitary liver cells and/or macrophages containing some Cu-positive 
granules, 2=small groups of liver cells and/or macrophages containing small to 
moderate numbers of Cu-positive granules, 3=larger groups or areas of liver cells and/or 
macrophages containing moderate numbers of Cu-positive granules, 4=larger areas of 
liver cells and/or macrophages with many Cu-positive granules, 5=diffuse presence of 
liver cells and/or macrophages with many Cu-positive granules. This classification was 
based on the system described by van den Ingh et al. (1988).   
 41 
 
7.3.5.  Criteria for MHC class II expression   
MHC class II antigen expression was evaluated in the liver sections of Dobermans 
suffering from chronic hepatitis and of control Dobermans, with special attention being 
given to the hepatocytes' ability to produce the molecule. The expression of MHC class 
II in liver samples was studied using an anti-human MHC class II antibody. This 
antibody is commercially available, works in paraffin-embedded sections, and has in 
previous studies been shown to cross-react with canine MHC class II antigen (Day 
1996, Tafti et al. 1996, German et al. 1998). To determine the relationship between 
inflammatory reaction and MHC class II expression in hepatocytes, expression was 
evaluated in the lobular areas. The number of hepatocytes expressing MHC class II in 
immunohistological staining was classified as shown in Table 3. 
Score Parenchymal area Periportal area Bridging necrosis area
0 None None None
1 Solitary hepatocyte expresses  Solitary hepatocyte around Solitary hepatocyte  adjacent
MHC class II portal area expresses MHC to bridging necrosis areas
class II expresses MHC class II
 
2 Small groups of  hepatocytes Small groups of  hepatocytes Thin band of  hepatocytes  
express MHC class II around portal area express adjacent to bridging necrosis
MHC class II areas expresses MHC class II
 
3 Moderate-sized groups of Less than 50% of circum- Obvious band of hepatocytes 
hepatocytes express MHC ference of most portal tracts adjacent to bridging necrosis
class II is involved areas expresses MHC class II
4 Large areas of hepatocytes More than 50% of circum- Thick band of hepatocytes  
express MHC class II ference of most portal tracts   adjacent to bridging necrosis 
is involved areas expresses MHC class II
5 Diffusely spread hepatocytes  
express MHC class II  
Table 3.  Grading criteria for major histocompatibility complex (MHC) class II expression in 
hepatocytes in liver specimens of Dobermans with hepatitis. 
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7.4.  Treatment 
In Study II, after the subclinical DH diagnosis had been confirmed, treatment was 
begun for seven of these dogs for which both biopsy and postmortem samples were 
available. The treatment consisted of prednisolon 0.1-0.5 mg/kg/day with or without d-
penicillamin 5 mg/kg/day. Prednisolon was given to five dogs for the entire follow-up 
period. D-penicillamin was stopped, for every dog, except one, months before 
euthanasia.   
 
In Study IV, seven Dobermans euthanized for end-stage DH had received 
corticosteroids (0.1-0.5 mg/kg/day) for 4-5 months before liver autopsy specimens were 
obtained. MHC class II expression in hepatocytes of these dogs were compared with 
expression in seven Dobermans euthanized for of end-stage DH that had received no 
treatment.   
  
7.5.  Statistical analyses    
 
Study I: The pair samples t-test and the Wilcoxon signed rank test were used to 
compare changes in blood parameters between the different stages during the 
subclinical period. The independent samples t-test and the Mann-Whitney U-test were 
used to evaluate differences between dogs with subclinical versus clinical DH.  
 
Study II: Histopathologic changes in the biopsies and in the postmortem liver samples 
from the same dogs were compared. Postmortem samples were further divided into two 
groups according to cause of death; five dogs died for reasons other than liver failure, 
and four dogs were euthanized because of advanced liver failure. The Wilcoxon signed 
rank test was used to study changes in histological parameters from biopsy sample to 
postmortem sample. The Mann-Whitney U-test served to evaluate differences in 
histological parameters between the two groups of postmortem samples.     
 
Study III:  The difference in hepatic quantitative Cu concentrations between the DH-
positive groups was compared by a two-sample t-test. The control group was compared 
with the DH groups by a two-sample t-test with unequal group variances. Differences in 
intensity of mononuclear inflammation and number of Cu-positive granules between 
 43 
 
centrolobular, periportal, and bridging necrosis areas were tested by Friedman two-way 
analyses of variance followed by a multiple comparison test. P-values less than 0.05 
were considered significant.  
 
Study IV: The Wilcoxon signed rank test was used when testing differences of MHC 
class II expression in hepatocytes between biopsy and autopsy samples, and the Mann-
Whitney U-test when testing the effect of treatment on MHC class II expression in 
hepatocytes. Spearman rank correlation coefficients were used to test the association 
between MHC class II expression and inflammation within areas. Results are expressed 
as means (+/- SD). P-values less than 0.05 were considered significant.  
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8.  RESULTS   
 
8.1. Criteria for subclinical DH 
 
Diagnosis of subclinical DH was based on four criteria. Dogs had to be clinically 
asymptomatic, with no signs of liver failure or any other disease at the time blood 
samples and the liver biopsy were taken. Dogs also had to have serum ALT values 
which were least three times the normal upper value in at least two consecutive samples. 
Histologically, an inflammation composed of mononuclear cells in the liver tissue must 
have present. And, finally, increased hepatic Cu content must here been observed by 
special stains.    
 
8.2.  Biochemistry  
 
8.2.1.  Serum parameters in the subclinical stage of DH 
A greater than threefold rise in serum ALT concentration was detected in 55 (8.8%) of 
the 626 randomly selected Dobermans. To investigate the reason for persistently 
increased ALT levels, a liver biopsy was obtained from 23 Dobermans. For 21 of these 
dogs, histological examination revealed hepatic changes compatible with the criteria set 
for DH.  
 
These 21 dogs with subclinical DH were followed up by evaluation of their ALT, AP, 
and total bilirubin values. The follow-up period, from the first blood sample to the first 
blood sample with clinical signs, lasted from 3 to 48 (average 19) months. The blood 
sampling interval ranged from one to six months. Altogether 102 blood samples were 
collected during this period.  
 
ALT values were recorded from all 102 blood samples. ALT values measured from 
these blood samples ranged from 87 to 2166 (normal value 15 to 85) U/l. The number of 
consecutive blood samples from the same dog in the subclinical period varied from 2 to 
10 (average 4.9) samples. The mean ALT of individual dogs ranged from 256 to 1575 
U/l. A marked variation was observed between consecutive samples, with ALT levels 
being very high in one sample but nearly normal in the next. However, in comparing 
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ALT in the first blood sample with that in the last in the subclinical stage, no significant 
(p>0.05) difference was present. In the follow-up, ALT did not return to the normal 
range in any of the dogs. Dogs that later developed clinical DH did not have higher 
ALT values in their first blood samples compared with dogs with subclinical DH that 
stayed asymptomatic.    
 
AP values, measured in 92 of the 102 blood samples, ranged between 134 and 3165 
(normal value 39 to 220) U/l. The consecutive AP value in the same dog ranged from 1 
to 10 (average 4.4) blood samples. The mean AP of individual dogs ranged from 297 to 
2119 U/l. The values for AP fluctuated during the follow-up, but as with ALT, in 
comparing the AP in the first blood sample with that in the last in the subclinical stage, 
no significant (p>0.05) change had occured. Three dogs had normal a AP value in the 
first blood sample. In the second and third blood samples, only one dog maintained a 
normal AP concentration. Thereafter, the AP of every dog increased.  
 
Total bilirubin values were measured for 15 of 21 dogs with subclinical DH. Thus, 
bilirubin was analyzed in 45 of the 102 blood samples. The values were in the normal 
range in 42 of these samples, ranging from 2.1 to 29.8 (normal values, 0 to 14 ) mmol/l. 
This blood parameter was analyzed from one to seven (average 3) times per dog. Mean 
total bilirubin of individual dogs ranged from 6.1 to 14.4 mmol/l.  
 
8.2.2.  Serum parameters in the clinical stage of DH  
Serum biochemistry was measured from 41 blood samples of 22 different Dobermans 
with clinical signs of chronic hepatitis. These 22 dogs included six who were initially in 
the subclinical stage but who during the follow-up showed signs of liver failure and 
were subsequantly euthanized because of DH. Sexteen dogs were diagnosed with DH 
only after the appearance of clinical signs.   
 
The follow-up period for the six dogs initially entering the investigation as subclinical 
patients but who later progressed to the clinical stage varied from 1 to 21 months. This 
period was measured from the first blood sample with clinical signs to the last sample 
before death. The survival time of these dogs, i.e.the time from the first blood sample 
with clinical signs until death ranged from 1.3 to 22 months. Altogether 16 blood 
samples were collected during this period from these six dogs.  
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The survival time i.e. the time from the first blood sample with clinical signs to death, 
of the 16 dogs diagnosed with DH only after clinical signs had appeared ranged from 2 
to 284 days. Altogether 25 blood samples were collected from these dogs. 
 
ALT values were recorded in all 41 blood samples during the clinical stage of DH. 
These values ranged from 279 to 2025 U/l. The number of consecutive samples taken 
from a single Doberman ranged from one to five (average 1.9). Mean ALT for 
individual dogs ranged from 279 to 1286 U/l. In 13 clinically affected dogs for whom 
more than one blood sample was collected, serum parameters for the first blood samples 
collected after onset of clinical signs were compared with those of the last samples 
before euthanasia. A decrease in ALT levels occured as the disease progressed, but the 
change was not significant (p>0.05). In none of the dogs was the ALT level in the last 
blood sample lower than three times the normal value. The lowest ALT value among 
these dogs in the clinical stage was 279 U/l, which is at least three times the normal 
upper value.  
 
AP values, determined from 40 blood samples in the clinical stage, varied from 403 to 
6776 U/l. The number of consecutive samples taken from a single Doberman ranged 
from one to five (average 1.8). Mean AP of individual dogs ranged from 501 to 5347 
U/l. In 13 clinically affected dogs for whom which more than one blood sample was 
collected, serum parameters for the first blood samples collected after onset of clinical 
signs were compared with those of the last samples before euthanasia. AP levels 
increased as the disease progressed, but this change was not significant (p>0.05).  
 
Total bilirubin levels were recorded for 18 of 22 Dobermans in the clinical stage of 
DH. Total bilirubin was analyzed from a total of 25 blood samples, with values ranging 
from 2.9 to 550.6 (normal value 0 to14) mmol/ l. Bilirubin concentration was normal 
only in four out of these blood samples. The number of consecutive samples taken from 
a single Doberman ranged from one to four (average 1.4). Mean total bilirubin of 
individual dogs ranged from 9.4 to 550.6 U/l.  
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8.2.3.  Serum parameters of subclinical versus clinical stages of DH 
The ALT values in the first blood samples of dogs in the subclinical stage of hepatitis 
were compared to ALT values measured in the first blood samples of dogs with clinical 
DH. No significant difference was observed (p>0.05). Comparison of all blood samples 
collected during the subclinical stage (n=102) with the corresponding samples collected 
during the clinical stage (n=41) yielded similar results (p>0.05).  
 
The levels of AP were, however, significantly higher among clinically affected dogs 
compared with the first blood samples of the dog with subclinical stage with the 
corresponding samples collected in the clinical stage of the disease (p<0.001). When 
comparing all blood samples collected in the subclinical stage (n=92) with those 
collected in the clinical stage of the disease (n=40), AP concentrations were 
significantly (p<0.001) higher among dogs with clinical DH.  
 
Bilirubin levels were significantly (p<0.001) higher among clinically affected dogs 
than among dogs with subclinical DH. 
 
8.3.  Evaluation of liver samples  
 
8.3.1.  Biopsy samples in DH      
Biopsy samples from dogs in the subclinical stage of DH were obtained via laparatomy. 
On macroscopical evaluation, the liver of all dogs with DH appeared normal in size, 
with a smooth and unremarkable surface. 
 
The most significant changes in the subclinical stage of DH were diffuse inflammation 
with multifocal clusters of inflammatory cells in the parenchymal area, and portal 
inflammation (Fig 1). The degree of parenchymal inflammation in most of the dogs was 
graded as moderate to marked. Most of the inflammatory cells were lymphocytes. 
Neutrophils and macrophages were also present, but the number of plasma cells was 
low. The parenchyma was usually not distorted. Portal inflammation was also moderate 
to marked.  In contrast to findings in the parenchymal and portal areas, lesions in the 
periportal areas were less severe. Periportal necrosis was generally mild to moderate, 
and the limiting plate surrounding the portal area was never markedly ruptured. Only 
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three dogs had bridging necrosis which appeared minimal. Portal expansion and fibrosis 
were not common findings, and when found, were usually mild. Bile duct proliferation 
was typically absent, being and recorded in only two of 18 biopsies. Intrasinusoidal bile 
plugs, as a sign of intrahepatic cholestasis, were evaluated at high magnification for 17 
samples. Bile plugs were noted in only two samples.   
 
The location of Cu-positive granules was evaluated in 17 dogs with subclinical DH 
using a rhodanine stain. Cu accumulation was observed in every biopsy sample. In the 
subclinical stage, the most numerous Cu-containing granules occured in the 
centrolobular area around the central vein. In only four of 17 liver samples was Cu 
observed in small groups of periportal hepatocytes. Bridging necrosis was demonstrated 
in five of the 17 samples, and Cu-positive granules were rarely seen in these areas.  
 
MHC class II expression was observed in the hepatocytes in 15 of 18 biopsy samples 
(83%). In the parenchymal area, in 10 of 15 positive cases, expression was noted only 
around the central vein. In the periportal area, MHC class II expression in hepatocytes 
was seen in seven of 15 DH cases. Bridging necrosis was noted in five biopsies, and 
MHC class II expression in hepatocytes was present adjacent to these necrosis areas in 
three samples. In the biopsy samples, the most prominent mode of expression for MHC 
class II was cytoplasmic, which was characterized by granules in the cytoplasm of 
hepatocytes (Fig 2). Membranous expression, indicated as a rim around hepatocytes, 
was seldom observed at this stage of the disease.  
 
In biopsy samples, MHC class II were also expressed by Kuppfer cells and 
lymphocytes. Only a few bile ducts in the portal areas expressed MHC class II.  
 
8.3.2.  Autopsy samples in DH  
In autopsy samples of Dobermans, from which the diagnosis of DH was made during 
the subclinical stage of the disease and an autopsy specimen was obtained when these 
dogs were eutahanized for reasons other than DH, inflammation in the parenchymal 
area was moderate in four dogs and minimal in one. Portal inflammation was moderate 
to marked. All dogs had at least moderate piecemeal necrosis. Bridging necrosis was 
detected in three samples, and in one of these, it was diagnosed as multilobular necrosis. 
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Although portal expansion was moderate to marked, bile duct proliferation was evident 
in only two dogs. One dog had cirrhosis. 
 
In those dogs for whom the diagnosis of DH was made in the subclinical stage and who 
were subsequently euthanized because of DH, the liver was clearly distorted, its surface 
covered with nodules. Histopathological findings were characterized by moderate to 
marked piecemeal and bridging necrosis. In one dog, multilobular necrosis was 
observed. Portal expansion was moderate to marked. In every sample, bile duct 
proliferation and fibrosis were also present. Although portal expansion was moderate to 
marked, in two dogs only small groups of cells or single inflammatory cells were 
randomly distributed in the parenchymal area. In two other dogs, multifocal 
parenchymal inflammation was moderate. All dogs had most of the inflammatory cells, 
which were composed of lymphocytes and macrophages, situated in the periportal and 
bridging necrosis areas (Fig 3). Bile plugs were observed in every autopsy sample 
obtained from these dogs (Study III). The number of plugs was 1+ in six samples and 
2+ in 17 samples.  
 
Cu was detected histologically in every autopsy sample of dogs with DH (II, III). In the 
clinical stage of DH, Cu was mainly located in the periportal and bridging necrosis 
areas (III).  
  
In the autopsy samples of all 20 dogs diagnosed with DH, hepatocytes expressed MHC 
class II molecules. Although MHC class II expression was also observed in the 
parenchymal area, the most obvious expression was noted in the hepatocytes adjacent to 
the periportal and bridging necrosis areas. The prominant staining pattern was a 
membranous rim around hepatocytes (Fig 4). Cytoplasmic staining patterns for anti-
MHC class II antigens were also seen.   
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Figure 1. Liver biopsy from a Doberman suffering from subclinical DH which shows scattered 
inflammatory cells in sinusoids and a cluster of cells in the parenchymal area. 
 
 
               
    
 
 
 
Figure 2. MHC class II expression in a liver specimen from a Doberman with subclinical DH. A focal 
group of hepatocytes around the central vein stained positive for MHC class II antigens. The inset shows 
staining for MHC class II molecules in hepatocyte 
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Figure 3. Postmortem liver sample from a dog euthanized for DH. The inflammatory reaction is located 
in the bridging necrosis area.  
 
             
 
 
Figure 4. Autopsy specimen from a Doberman euthanized for DH. No immunosuppressive medication 
was received before euthanasia. Hepatocytes staining positively for MHC class II antigens were adjacent 
to bridging necrosis areas with mononuclear cell infiltration. The inset reveals a rim around the 
hepatocytes, denoting membranous staining of MHC class II molecules. 
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8.3.3.  Biopsy versus autopsy samples in DH   
In five of the dogs for whom diagnosis of DH was made in the subclinical stage but who 
were subsequently euthanized for reasons other than DH, the time between biopsy and 
autopsy samples ranged from 3.5 to 65 months. Four dogs diagnosed with DH in the 
subclinical stage subsequently developed clinical signs of liver failure 5 to 35.5 months 
after the biopsy  and were euthanized 0.5 to 20.5 months later. In all nine of these dogs, 
the disease has progressed. Comparing histopathological changes in these dogs with 
both the biopsy and the postmortem sample, the most notable changes were expanded 
portal areas (p=0.008), increased periportal and bridging necrosis (p=0.008), increased 
fibrosis (p=0.016), and increased proliferation of bile ducts (p=0.063). Diffuse 
inflammation with clusters of inflammatory cells in the parenchyma tended to occur 
more often in biopsy than in postmortem samples, but this difference was not significant 
(p=0.250) (II).  
 
When comparing Cu accumulation between biopsies obtained in the subclinical stage of 
DH and autopsies obtained after euthanasia because of DH, accumulation was higher in 
the periportal and bridging necrosis areas of autopsy samples (III). The values in biopsy 
and autopsy specimens in periportal areas were 0.5 and 1.8, respectively. The 
corresponding values in bridging necrosis areas were 0.8 and 2.4. By contrast, in 
parenchymal areas, Cu granules were fewer in autopsy than in biopsy samples. The 
values in biopsy and autopsy specimens in parenchymal areas were 2.6 and 1.4, 
respectively. Comparing staining patterns of Cu granules, patterns were ‘’pathy-like’’ in 
biopsy samples and ‘’network-like’’ in autopsy samples.   
 
From 10 Dobermans, both biopsy and autopsy samples were available for evaluating 
changes in MHC class II expression during disease progression. In two dogs, 
hepatocytes showed no positive staining for MHC class II in biopsy specimens. 
However, in the autopsy samples of both dogs, hepatocytes did express MHC class II 
molecules. The intervals between biopsy and autopsy specimens for these two dogs 
were 3.5 and 57 months. In the remaining eight dogs, the amount of MHC class II 
expression in hepatocytes in the parenchymal area did not differ significantly between 
biopsy and autopsy samples. In the periportal area (p<0.05) and the region adjacent to 
bridging necrosis areas (p<0.05), by contrast, MHC class II expression increased 
significantly in hepatocytes during disease progression. In these dogs, biopsy and 
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autopsy samples were taken from 5.5 to 65 months apart. MHC class II expression in/on 
hepotocytes was greater when the interval between the biopsy and autopsy was larger. 
However, the correlation (rs=0.49) was not statistically significant (p>0.15). 
 
8.3.4.  Liver samples of control Dobermans 
In the biopsy of two Dobermans with elevated ALT values in consecutive blood 
samples, neither inflammation nor copper accumulation was observed in liver tissues. 
Histological findings instead revealed vacuolization of liver cells (II). Studies III and IV 
also revealed no inflammation in liver samples of control Dobermans. 
  
In two Dobermans, euthanized because of adenocarcinoma in the beginning of 
duodenum or dilatation and torsion of the stomach, some Cu granules were present in a 
few hepatocytes (III).  
  
In the control Dobermans, no MHC class II molecules were detected in hepatocytes or 
endothelial cells of bile ducts. However, Kupffer cells and the few existing mononuclear 
leukocytes in the sinusoids did express MHC class II molecules.  
 
8.3.5.  Relationship of mononuclear inflammation to liver copper  granules   
A spatial relationship was found between the inflammatory reaction and Cu 
accumulation in DH. In the subclinical stage of the disease, when inflammation was 
most prominent in the parenchymal area, Cu accumulations were also observed in the 
same location. The grades for these parameters were 3.2 and 2.6, respectively. In the 
periportal area, only a small propotion of the limiting plates were destroyed and 
inflammation was present. Cu was seldom seen in these areas. Bridging necrosis and 
inflammation were also rare findings in the subclinical stage. Only a small amount of 
Cu was present in two samples. In the periportal and bridging necrosis areas, 
inflammation and Cu were scored as 1.8 and 0.5 and 0.5 and 0.8, respectively.  
 
In the clinical stage of DH, inflammation and Cu were mainly located in the periportal 
and bridging necrosis areas. The mean grades for inflammation and Cu in the different 
areas were the following: parenchymal area 1.9 and 1.4, periportal area 3.3 and 1.8, and 
bridging necrosis area 3.4 and 2.4.      
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8.3.6.  Relationship of mononuclear inflammation to MHC class II expression in 
hepatocytes 
In all biopsy samples, diffuse inflammation with multifocal clusters of mononuclear 
inflammatory cells in the parenchymal area was observed. When evaluated by density 
of cells, the mean value for inflammation was 2.2 (SD 0.8, scale 0-3). The mean value 
in the same area for MHC class II expression in hepatocytes was graded as 1.9 (SD 1.5, 
scale 0-5). In the periportal region, the mean index for mononuclear cell infiltration was 
1.4 (SD 0.6, scale 0-3). MHC class II expression in hepatocytes was seen in seven of  15 
DH cases. The mean value for expression was graded as 0.8 (SD 1.2, scale 0-4). 
Bridging necrosis was noted in five biopsies. Weak MHC class II expression in 
hepatocytes was present adjacent to bridging necrosis areas in three DH samples.  
 
When numerically evaluating the lobular area consisting of parenchymal, periportal, and 
bridging necrosis areas, a correlation was observed between MHC class II expression in 
hepatocytes and mononuclear cell inflammation (p<0.05). Upon dividing the lobular 
area into subsections, the positive correlation was found to be contained within the 
periportal area (p<0.05) and between hepatocytes adjacent to the bridging necrosis area 
and mononuclear cell inflammation in bridging necrosis areas (p<0.05).  
 
In autopsy samples, the level of cell infiltration was graded as 1.6 (SD 0.6, scale 0-3) in 
the parenchymal area. The mean level of MHC class II expression was graded as 2.4 
(SD 1.3, scale 0-5). Mean values for mononuclear cell infiltration in periportal and 
bridging necrosis areas were 2.3 (SD 0.7, scale 0-3) and 1.9 (SD 0.9, scale 0-3), 
respectively. Mean values for MHC class II expression in these areas were 2.9 (SD 1.2, 
scale 0-4) and 2.8 (SD 1.2, scale 0-3), respectively.   
  
A positive correlation between inflammation and MHC class II expression in 
hepatocytes was observed in the lobular area (p<0.05), in the parenchymal area 
(p<0.05), and between hepatocytes adjacent to bridging necrosis areas and mononuclear 
cell inflammation in bridging necrosis areas (p<0.05).   
 
 55 
 
8.3.7.  Comparison of rubeinic acid and rhodanine stains for copper detection   
In 19 of 40 liver samples (47.5%), rubeinic acid demonstrated a stronger positive 
reaction than rhodanine to Cu. In 19 cases (47.5%), the stains were equal, and in two of 
40 cases (5%) rhodanine gave a stronger stain.  
 
8.3.8.  Evaluation of hepatic copper concentrations   
In control Dobermans, hepatic Cu levels ranged from 27 to 352 (mean 226) µg/g dw. In 
dogs in the subclinical stage of DH, hepatic Cu content ranged from 430 to 2157 (mean 
1097) µg/g dw and in dogs euthanized because of DH from 630 to 4155 (mean 1768) 
µg/g dw. When between different groups were compared, Cu content in controls was 
found to be significantly lower than in dogs in the subclinical stage of DH or those 
euthanized because of DH. Furthermore, Cu content was significantly greater in the 
end-stage than at the beginning of the disease.    
 
8.4.  Effect of corticosteroid treatment in DH 
 
Seven dogs with DH for whom both biopsy and autopsy samples were available were 
treated with a small dose of a corticosteroid drug (II). While the medication scheme 
varied among the dogs, it was obvious that these treatment programs failed to halt 
progression of the disease.   
 
Fourteen Dobermans were euthanized because of advanced chronic hepatitis. Seven of 
these dogs had received prednisolon (0.1-0.5 mg/kg/day) for 4 to 5 months. In 
untreated, euthanized Dobermans, the mean values for MHC class II expression in 
hepatocytes in lobular, parenchymal, and periportal areas and in regions adjacent to 
bridging necrosis areas were 10.3 (SD 2.6), 3.3 (SD 1.4), 3.4 (SD 1.1), and 3.6 (SD 0.8), 
respectively. A thick band of hepatocytes adjacent to the bridging necrosis areas was 
also recorded to express MHC class II. In Dobermans treated with corticosteroids before 
euthanization, scattered hepatocytes or small groups of hepatocytes expressed MHC 
class II. The mean values for MHC class II expression in hepatocytes in lobular, 
parenchymal, and periportal areas and in regions adjacent to bridging necrosis areas 
were lower than in untreated animals, being 6.9 (SD 2.6), 1.6 (SD 1.1), 2.9 (SD 0.9), 
and 2.4 (SD 1.0), respectively. Thus, prednisolon treatment had significantly decreased 
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the hepatocytes’ ability to express MHC class II in the lobular area (p<0.05), the 
parenchymal area (p<0.05), and region adjacent to bridging necrosis areas (p<0.05). 
Among untreated Dobermans, the correlation (rs=0.82) between MHC class II 
expression in/on hepatocytes and mononuclear cell infiltration in the lobular area was 
significant (p=0.024). Among Dobermans treated with corticosteroids before 
euthanasia, the correlation was also positive (rs=0.33) but not statistically significant 
(p=0.47).  
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9. DISCUSSION   
 
DH is a chronic liver disorder which most often affects female Dobermans (Johnson et 
al. 1982, Crawford et al. 1985, Fiorito 1985, Cornelius 1989a). Although the disease can 
be detected during routine screening of biochemical profile before a surgical procedure, 
it is usually diagnosed when the dog already has clinical signs of liver failure (Meyer et 
al. 1980, Doige and Lester 1981, Johnson et al. 1982, Crawford et al. 1985, van den 
Ingh et al. 1988, Cornelius 1989a, Fuentealba et al. 1997). The prognosis is poor in the 
clinical stage, and despite treatment with corticosteroids, the dog’s condition will 
deteriorate requiring euthanasia (van den Ingh et al. 1988, Rothuizen 1997). 
 
While reports have been published on Dobermans with clinical signs of hepatitis, scant 
information is available on dogs in the subclinical stage. The most commonly analyzed 
liver enzymes are ALT and AP, both of which are typically elevated in DH (Meyer et al. 
1980, Doige and Lester 1981, Johnson et al. 1982, Thornburg et al. 1984, Crawford et 
al. 1985, van den Ingh et al. 1988, Thornburg 1988, Cornelius 1989a, Röcken et al. 
1991, Fuentealba et al 1997). No data are available, however, on which enzyme is 
superior in diagnosig Dobermans in the subclinical stage. In addition, follow-up studies 
on how biochemical parameters change during disease progression are practically 
nonexistent. 
 
Since the prognosis of DH in the clinical stage is very poor, detection of affected 
individuals in the asymptomatic subclinical stage is essential. Identifying these dogs is 
beneficial both for the breed as for individual dogs. The high prevalence of chronic 
hepatitis in Dobermans suggests a genetic background (Johnson et al. 1982, Thornburg 
et al. 1984, Hardy 1985). Dogs in the subclinical stage can easily be used for breeding. 
If DH is considered a hereditary disease, testing Dobermans for the disease before 
mating would lower the health risk of future offspring.   
 
The dog itself will also benefit from early diagnosis of DH because it will probably 
prolong survival time. Environmental factors may also affect DH development, 
although specific effects are unknown (Crawford et al. 1985). Such environmental 
factors as nutrition and future medication can be tailored according to the dog’s health 
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status. Pregnancies and unnecessary operations should be avoided. If an operation is 
needed, consideration must be given to the underlying disease.  
 
9.1.  Serum parameters   
   
Serum ALT, AP, and total bilirubin levels were evaluated in dogs diagnosed in the 
subclinical stage of DH.  These parameters were compared with those obtained from 
dogs in the clinical stage to evaluate changes during disease progression. 
 
Based on our findings, dogs with subclinical DH  can be identified by regular testing of 
ALT and AP. The procedure can be performed during annual vaccination visits, and the 
benefits will far outweigh any costs. However, it should be noted that elevated liver 
enzyme values are not pathognomonic of DH and can be observed in many other 
disorders affecting the liver (Dillan 1985, Twedt 1998). Definitive diagnosis should 
therefore always be based on a liver sample.  
 
Based on our results, ALT is the best screening test for DH. Although both ALT and AP 
values are routinely evaluated in suspected cases of  DH, ALT is the first liver enzyme 
to rise. Unlike ALT, AP levels can be normal in the initial stages of the disease. 
Therefore, an evaluation of AP alone might result in the misdiagnosis of a patient with 
DH.   
 
Although ALT is an effective enzyme for screening dogs with subclinical DH, it cannot 
be used for predicting disease progression from the subclinical to the clinical stage, 
because ALT values can be abnormal for several months or even years before a dog has 
any clinical signs. During this period the values may fluctuate frequently. In this study, 
despite fluctuation, ALT values did not return to the normal range. In addition, no 
significant difference was present in serum ALT levels between the subclinical and 
clinical stages of DH. 
 
According to the literature, normal ALT activity does not rule out the possibility that a 
dog has chronic hepatitis (Fuenteable et al. 1997). Our findings do not, however, 
support this assumption. We found ALT levels to decrease as clinical signs became 
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more severe. However, before euthanasia, none of the Dobermans with obvious signs of 
advanced liver failure, such as ascites, jaundice, and severe cahexia, had ALT levels in 
the normal range. This indicates that normalization of serum ALT concentration is rare 
even in the end-stages of the disease in Dobermans. Our finding is supported by 
previously published results (Meyer et al. 1980, Doige and Lester 1981, Johnson et al. 
1982, Thornburg et al. 1984, Crawford et al. 1985, van den Ingh et al 1988, Thornburg 
1988, Cornelius 1989a, Röcken et al 1991, Fuentealba et al 1997). In the clinical stage 
of the disease, only three of 74 blood samples (0.04 %) had ALT values in the normal 
range.  
 
AP levels may be increased for several months or years even though the dog is 
asymptomatic. Similarly to ALT, AP is not a very good prognostic indicator for disease 
progression at the individual level despite AP values at group level being significantly 
higher in the clinical stage of DH than in the subclinical stage. While AP is elevated 
throughout diskase, it is common for values  to fluctuate from sample to sample. The 
increase in serum AP concentration might be due to increased alteration in parenchymal 
structure and induction of AP from hepatocytes and bile duct cells. The elevation in AP 
values seen in this study could also be due to the corticosteroid treatment that some of 
the dog received.  
 
Total bilirubin values are not routinely analyzed in Dobermans with hepatitis, especially 
if dogs are not clinically icteric (Meyer et al. 1980, Crawford et al. 1985, Cornelius 
1989a, Röcken et al. 1991). Based on our results, however, serum total bilirubin levels 
should also be routinely tested in dogs suffering from subclinical or clinical DH. 
Although this value is not used in screening dogs with subclinical DH, it can provide 
additional insight into progression of the disease after DH is confirmed by liver biopsy. 
Total bilirubin is a better indicator than ALT or AP for predicting disease progression 
from the subclinical to the clinical stage. Here, total bilirubin levels were normal in 
dogs with subclinical DH. Total bilirubin values stayed within the normal ranges for 
several months or years despite increased ALT and AP values. However, when dogs 
exhibited clinical signs of liver failure, total bilirubin levels were invariable abnormal. 
In comparing total bilirubin values between the subclinical and clinical stages, the 
differences were significant. It is therefore advisable in re-examinations of patients to 
check serum total bilirubin levels in addition to the liver enzymes previously mentioned. 
 60 
 
Because corticosteroid treatment can normalize total bilirubin values of dogs in the 
clinical stage of DH (Center 1996b), the value of this measurement in treated dogs is 
limited. 
 
DH can be divided into subclinical and clinical stages based on clinical and biochemical 
results (Speeti 1998). In addition, serum biochemical values are indicative of 
progression of DH when no treatment is used. Once continuously elevated ALT and AP 
values are confirmed by liver biopsy to be caused by DH, the biochemical profile of the 
patient should be re-evaluated at least twice a year to keep abreast of disease 
progression of the. Increased serum ALT concentration followed by increased AP but 
normal bilirubin, is typical of the subclinical stage. Abnormal bilirubin can predict the 
advancement of DH to the clinical stage.     
 
The results here can be used on a practical level when examining dogs with clinical 
signs resembling those of DH. First, a dog with elevated serum AP but normal ALT is 
probably suffering from something other than DH. This suggestion is further supported 
if the total bilirubin value is normal. Second, if a Doberman with clinical signs has both 
increased ALT and AP values, but consecutive serum total bilirubin concentrations are 
normal, it is this author’s opinion that the dog’s clinical signs are most likely not due to 
DH. This conclusion is based on the findings that in the clinical stage of DH total 
bilirubin values were always abnormal. In addition,  the liver has been shown to easily 
be secondarily affected by extrahepatic diseases. In these reactive hepatopathies, bile 
acids are usually normal, but definitive diagnosis is based on a liver biopsy which 
reveals histological findings different from those in DH. It is also noteworthy that 
clinically affected Dobermans with increased ALT and AP values but consecutive 
normal total bilirubin values may show characteristic histological findings of subclinical 
DH in biopsy samples. This merely indicates that this patient with subclinical DH has a 
concurrent disease which is actually the reason for the clinical signs. 
 
9.2.  Diagnosis of subclinical DH  
  
Definitive diagnosis of DH should be based on the results of a liver biopsy. Previous 
research examining histological changes of the liver has focused on patients with 
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clinical signs of liver failure (Meyer et al. 1980, Doige 1981, Johnson et al. 1982, 
Crawford et al. 1985, Fiorito 1985, van den Ingh et al. 1988, Cornelius 1989a, 
Fuenteable et al. 1997). Our study comprised histological descriptions of 18 dogs with 
subclinical DH., the Histological findings in all these dogs differed from those 
described in the literature regarding Dobermans with clinical signs of liver failure. In 
the subclinical stage of DH, the most prominent feature was mononuclear inflammation 
in the parenchymal and portal areas. Also typical of subclinical DH is that the limiting 
plate composed of a layer of single hepatocytes surrounding the portal areas was  
mostly intact. This finding differs from those previously published which assume that 
limiting plate necrosis is an important aspect in chronic hepatitis of Dobermans 
(Johnson et al. 1982, Sarli 1992). Our results also indicate that the inflammatory process 
starts in the centrolobular area. Our observations resemble those of Thornburg (1998), 
who reported the presence of inflammatory cells in the central area. However, in this 
article, the first inflammatory cells had been noted in the walls of hepatic veins and 
around nearby hepatocytes.  
 
The diagnosis of subclinical DH here was based on four criteria. First, dogs were 
clinically asymptomatic. No signs of liver failure or any other disease were observed 
when blood samples were taken or at the time of liver biopsy. Second, dogs had 
consecutive ALT values which were at least three times the normal upper value. We 
recommend that at least a three fold elevation in ALT values be recorded in consecutive 
blood samples before a liver biopsy is performed on an otherwise healthy Doberman. 
This is because with only mildly elevated ALT levels the histological findings will be 
so minor that a definitive diagnosis probably cannot be made. Third, inflammation 
composed of mononuclear cells was present in liver tissue. Fourth increased hepatic Cu 
content was observed by special stains. 
 
DH  was shown in this study to be a progressive disease. The literature has described 
dogs with lobular hepatitis without bridging necrosis or cirrhosis that undergo 
spontaneous remission. Their increased ALT values can return to normal in 4 to 10 
weeks (Thornburg 1988). Here, ALT value was measured 3 to10 (mean 6) times in all 
18 dogs in the subclinical stage of DH. Altogether 108 blood samples were evaluated. 
In all samples, ALT was abnormally high, and in 93%, it was three times the normal 
value.  
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Autopsy liver samples were evaluated for nine out of the 18 Dobermans diagnosed in 
the subclinical stage of DH. The time between biopsy and autopsy samples ranged from 
3.5 to 65 months. By comparing the histological lesions of biopsy and autopsy samples 
from the same dog, liver destruction was clearly seen to have progressed in every dog. 
These observations indicate that when a Doberman has consistently elevated ALT 
values and biopsy reveals portal inflammation, diffuse to multifocal parenchymal 
inflammation, and increased copper levels the dog is suffering from subclinical DH. 
Because the disease is progressive in nature, the dog may get clinical signs and 
histological examination will then reveal features typical of chronic hepatitis, including 
piecemeal and bridging necrosis, fibrosis, and cirrhosis.      
 
A scoring system, commonly used in human medicine to compare lesions in different 
samples from patients suffering from viral hepatitis, was used for the evaluation of 
histological lesions in dogs with DH. This method, a modified version of the system 
created by Knodell (1981), allowed for effective evaluation of progression of 
histological lesions in the subclinical stage of DH. This scoring system is not widely 
used in veterinary medicine. However, an evaluation system where different lesions 
have different numerical values based on their severity is the only objective way of 
determining whether a disease is progressing (Desmet et al. 1994, Brunt 2000, Jevon 
2001). Its usefulness is also obvious when evaluating the possible effect of different 
medications and environmental agents, such as nutrition and stressful events, on the 
progression of DH. 
 
Subclinical DH was diagnosed  in 21 of 23 Dobermans with continuously  elevated 
ALT values. In the liver biopsies of two dogs, no inflammation or Cu was observed; 
histological findings were instead dominated by vacuolization of liver cells. These two 
dogs may have had some extrahepatic disorder causing the elevation in liver enzyme 
values. Alternatively, DH may have been in a very early stage, with histological features 
not yet fulfilling the criteria established for diagnosis of subclinical DH. Based on these 
two Dobermans with elevated ALT values, the diagnosis of subclinical DH should 
always be based on the findings in liver biopsy. 
 
Since morphological findings, such as the marked piecemeal necrosis typical of CAH 
were absent from all of our biopsies, we preferred to use the term Doberman hepatitis 
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for this entity. The absence of prominent periportal inflammation in biopsy samples of 
dogs with chronic hepatitis has also been noted by others who criticize the use of the 
term ‘’chronic active hepatitis’’ for dogs (Sevelius 1995). 
 
9.3.  Role of copper in DH  
  
Copper is an essential trace element for humans as well as dogs, but excessive amounts 
can be very harmful (Linder and Hazegh-Azam 1996, Richter 2003). Cu concentration 
in the body is therefore strictly controlled. Normal canine liver Cu levels are assumed to 
be under 400 µg/mg dw, and at this level, Cu cannot be detected histologically by 
special stains (Twedt et al. 1979, Thornburg et al. 1985, Rolfe and Twedt 1995). In DH, 
increased hepatic Cu content has been reported both by measuring liver Cu levels and 
by histological staining, but its role in this disease remains unknown (Doige and Lester 
1981, Johnson et al. 1982, Thornburg et al. 1984, Crawford et al. 1985, Hardy 1986, van 
den Ingh et al. 1988, Cornelius 1989a). These concentrations have been measured 
mainly from dogs in the clinical stage of DH. Liver Cu concentrations in Dobermans 
rarely reach the levels found in Bedlington Terriers, who suffer from an inherited, 
primary Cu metabolic disorder. Elevated hepatic Cu content was also observed in this 
study. However, contrary to previous reports where Cu was detected mainly in the 
clinical stage of DH, here it was recorded in both the subclinical and clinical stages of 
DH. 
 
Three theories as to why liver Cu content is elevated in DH predominate. The most 
common of these is that increased hepatic Cu content is caused by chronic intrahepatic 
cholestasis (Johnson et al. 1982, Cornelius 1989b, Sarli 1992, Center 1996b). This 
suggestion is based on findings from the clinical stage of the disease. In this stage, 
increased hepatic Cu content has been noted around the portal area or in the periphery 
of the pseudolobulus surrounded by bridging necrosis areas. Bile plugs in the liver 
tissue and increased serum bilirubin values are other common findings in the clinical 
stage. 
  
Our observations from the subclinical stage of DH do not support the cholestatic theory. 
Increased liver Cu content was always detected already in the subclinical stage. In this 
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stage, Cu was located in the parenchymal area, whereas periportal areas were mainly 
intact. Bridging necrosis areas were absent in the subclinical stage. 
 
Bile plugs are considered signs of intrahepatic cholestasis because their formation arises 
from impaired bile flow (Johnson et al. 1982, Fiorito 1985). Our findings indicate that 
intrahepatic cholestasis is not present in the subclinical stage of DH. Bile plugs were 
absent in all but one Doberman in the subclinical stage. It is furthermore supposed that 
bile plugs in the canaliculus may vanish during the laboratory processing of the liver 
tissue. However, since intracanalicular bile plugs were observed in only 5.8% of 
samples in the subclinical stage but 100% of samples in the clinical stage, laboratory 
processing is unlikely to be the reason for the absence of bile plugs in subclinical DH. 
The lack of bile plugs in subclinical dogs is supported by other studies (Thornburg et al. 
1984, Fuentealbe et al. 1997). 
   
Chronic intrahepatic cholestasis as a cause for increased Cu in DH has also been 
suggested as a result of DH being compared with chronic cholestatic liver disorders, 
such as primary biliary cirrhosis (PBC), in humans (Johnson et al. 1982, Sarli 1992). In 
PBC, the main targets for destruction are medium-sized bile ducts. The damage to bile 
ducts eventually leads to intahepatic cholestasis (Kaplan 1993). Comparing PBC with 
DH, Cu accumulation is in the periportal area, rather than the parenchymal area, and 
accumulation is typically observed in the later stages of the disease, whereas in DH Cu 
levels are elevated already in the subclinical stage. Therefore, the reason for Cu 
accumulation is different in these two liver disorders. 
 
Elevated serum bilirubin level is also considered a sign of cholestasis (Meyer et al. 
1980, van den Ingh et al. 1988) since bilirubin is secreted via bile and reduced bile flow 
causes the elevation in bilirubin values. However, 94% of the Dobermans in the 
subclinical stage had total bilirubin levels in the normal range. This indicates that 
hyperbilirubinemia is a rare finding at the beginning of DH, contradicting the 
cholestatic theory of Cu accumulation in DH.  
 
Cu accumulation in DH has also been suggested to occur because of a primary 
metabolic defect based on a study of two Dobermans with subacute hepatitis. Increased 
hepatic Cu was observed in the centrolobular area and no signs of intrahepatic 
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cholestasis were present (Thornburg 1984). In humans, Wilson’s disease, and in dogs, 
Bedlington Terriers’ Cu toxicosis, are disorders of primary Cu metabolism. In both 
diseases, Cu secretion from hepatocytes is abnormal, resulting in progressive Cu 
accumulation in the liver (Twedt 1997, Subramanian et al. 2002, Richter 2003). Hepatic 
destruction usually does not occur until Cu concentration has exceeded the hepatocytes’ 
ability to bound free Cu. Unbound Cu causes damage to hepatocytes, inducing 
inflammation (Brewer 2000, Richter 2003). In Bedlington Terriers, hepatic damage is 
not evident until Cu levels exceed 2000 µg/mg dw (Thornburg 2000). 
 
Our observations do not support the hypothesis that DH is a primary Cu metabolic 
disease such as the one seen in Bedlington Terriers. Mononuclear infection in liver 
tissue was obvious despite Cu concentrations being lower than 1500 µg/mg dw. Also, 
according to the literature, hepatic Cu concentrations in DH rarely reach the 
concentrations reported in Bedlington Terriers (van den Ingh et al. 1988, Sevelius et al. 
1993). Other differences between DH and primary Cu metabolic diseases also exist. D-
penicillamine is widely used to treat Wilson’s disease and Cu toxicosis in Bedlington 
Terriers. It chelates with Cu in the blood and tissues, causing secretion of Cu into the 
urine (Twedt 1997). D-penicillamine is effective for preventing chronic hepatitis and 
cirrhosis in both of these primary Cu metabolic disorders (Subramanian et al. 2002, 
Richter 2003). However, its effect on DH has thus far not been well studied (Crawford 
et al. 1985, Center 1996). 
 
Finally, Cu in DH has been argued to have no clinical relevance, merely an incidental 
finding. This is based on a report of five of 35 Dobermans with chronic hepatitis having 
either normal hepatic Cu concentration or no detected Cu in rhodanine-stained sections 
(Thornburg 1998). In contrast to the above, in our study, elevated hepatic Cu 
concentration was observed using a special stain in every sample obtained from 18 dogs 
with subclinical DH and in 20 out of 21 samples from dogs with clinical DH. In the 
control group, no Cu accumulation was detected in histological examination. Hepatic 
Cu concentration was also quantitatively measured in both the subclinical and the 
clinical stages of DH as well as in control Dobermans. Cu appeared to increase as the 
disease progressed; in control Dobermans, concentrations did not exceed 400 µg/mg 
dw. In our opinion, elevated hepatic Cu concentrations in DH are not, therefore, 
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incidental. In fact, elevated hepatic Cu content was one of the criteria for diagnosing 
subclinical DH in this study. A later study on subclinical DH also noted consistently 
elevated hepatic Cu content (Mandigers 2000).  
  
Our result showed that increased hepatic Cu content was associated with tissue 
inflammation. A spatial relationship was observed between these two parameters. 
Moreover, the finding that corticosteroid treatment alone can decrease hepatic Cu 
content in DH supports the theory that a connection exists between hepatic tissue 
inflammation and Cu accumulation in DH (Center 1996b). By reducing tissue 
inflammation, corticosteroids most probably also decrease the Cu content of the liver. 
Corticosteroid treatment may explain why in some published research the copper levels 
in DH have been recorded within the normal range. We assume that Cu accumulation 
results because of tissue inflammation and not vica versa. Cu is proposed to accumulate 
in hepatocytes because mononuclear inflammation has disturbed the movement of Cu 
from hepatocytes to the bile canaliculus.  
 
Two histological stainings for Cu, rubeinic acid and rhodanine, were compared. Based 
on our results, the former seems to be more sensitive to Cu-positive granules. Rubeinic 
acid stain is therefore routinely used by the author to diagnose subclinical DH when 
histologically evaluating the possible existence of increased Cu in the liver section is 
important.   
 
9.4.  MHC class II expression in hepatocytes and etiology of DH 
    
Information regarding the etiology of DH is sparse. Here, etiological background of DH 
was analyzed based on findings of abnormal MHC class II expression in hepatocytes in 
different stages of DH. In this evaluation, a classification similar to that in humans 
suffering from chronic hepatitis was used.  
 
MHC class II molecules are normally expressed by professional antigen-presenting cells 
(APCs), including B-lymphocytes, macrophages, and dendritic cells. In dogs, MHC 
class II expression is also observed in T-cells without activation of the cells (Doveren 
1985, Tizard 1996). While hepatocytes typically do not express MHC class II antigens 
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(Spengler et al. 1988, Tizard 1996), here, in 87% of the biopsies taken in the subclinical 
stage of DH and in 100% of autopsy cases, MHC class II antigens were present in 
hepatocytes.  
 
MHC class II expression by non professional APCs can be due to microbes, drugs, 
toxins, or autoimmunity. Adenovirus-1 is the best-known viral cause of chronic 
hepatitis in dogs. Canine adenovirus-1 infections in dogs have not, however, been 
diagnosed in Finland for several years. This microbe cannot therefore be considered a 
stimulus for MHC class II expression in DH in this study. Other viruses have also been 
suggested as etiological factors in DH (Rothuizen 1997). Although a virus as a primary 
source of antigen for MHC class II expression in DH cannot be ruled out, some findings 
contradict a viral etiology. When a virus infects a cell, the antigen derived from the 
virus is mainly presented by MHC class I molecules, not MHC class II molecules, to T-
cells (Tizard 1996). If DH were a primary viral hepatitis, corticosteroid treatment would 
be contraindicated because corticosteroids suppress the immune response necessary for 
effective elimination of the virus. Dobermans in the subclinical stage of chronic 
hepatitis may be on a corticosteroid treatment for long periods without deterioration of 
health status. Furthermore, Dobermans with clinical signs of liver failure can show 
temporary improvement with corticosteroid treatment. Lastly, if DH were a primary 
viral hepatitis, other breeds would be expected to contract this infection at the same 
frequency as Dobermans.  However, chronic hepatitis is far more common in 
Dobermans than in most other breeds.  
 
Leptospires are a potential agent for causing chronic hepatitis in Dobermans. However, 
leptospirosis is diagnosed in Finland in only a few cases annually, mainly in dogs that 
have travelled abroad. Therefore, this microbe is an unlikely antigen source for MHC 
class II in hepatocytes of DH-positive dogs of this study.   
  
Drugs, toxins, or environmental chemicals can also stimulate MHC class II expression. 
Hepatocytes have the ability for the pinocytosis of drugs and toxins from the portal 
blood. However, a drug or a toxin as a noxious stimulus in DH was ruled out on the 
basis of several findings. First, dogs with elevated liver enzymes and subclinical DH 
were not taking medication and had no history of toxic exposure prior to the recording 
of elevated liver enzyme values or at the time of liver biopsy. Second, for stable MHC 
 68 
 
class II molecules, continuous antigen exposure is necessary, otherwise the molecule 
would dissolve into parts and vanish (Germain and Hendrix 1991). In our study, MHC 
class II expression in hepatocytes was observed both in the biopsy and autopsy samples 
of the same 10 dogs. The time between biopsy and autopsy specimens varied from 3.5 
to 65 months. During this interval MHC class II expression in hepatocytes persisted and 
got stronger. These dogs were not on any kind of medication, except possibly for 
corticosteroids during follow-up. These observations indicate that the stimulus for MHC 
class II expression in hepatocytes was permanent, thereby ruling out drugs as a 
causative agent. Third, in the subclinical stage of DH, expression of the MHC class II in 
hepatocytes was noted in the centrolobular area, whereas periportally, the hepatocytes 
appeared negative for expression. If the antigen arrived through the portal vein, the first 
hepatocytes to be affected would be around the portal area. This finding further 
discounts toxins as a potential cause of DH.  
 
In humans, aberrant expression of MHC class II in various tissues has been implicated 
in the pathogenesis of autoimmune  diseases (Rask et al. 1991, Nepon 1993, McDevitt 
1998). The finding that MHC class II molecules are expressed in hepatocytes in DH is 
therefore a strong indicator of an autoimmune background for this disease. Since the 
major function of MHC class II is to present antigens to T-cells, in DH this antigen is 
most likely an autoantigen of hepatocytic origin.   
 
Other evidence also favours the autoimmune nature of DH. First, females are more 
susceptible than males to DH (Johnson et al. 1982, Crawford et al. 1985, Fiorito 1985). 
Likewise, in human autoimmune diseases, a female preponderance is common. Second, 
Dobermans seem to have a genetic predisposition to chronic hepatitis. An association 
between different diseases, especially those autoimmune in nature, and MHC class II is 
well established in human diseases (McDevitt 1998). Thus, in DH, genetic 
predisposition is also most likely associated with MHC class II genes. Third, antibodies 
against liver-specific protein have previously been observed in two of four Dobermans 
examined that suffered from chronic hepatitis (Weiss et al. 1995).   
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9.5.  MHC class II expression in hepatocytes and pathogenesis of DH  
 
At present, no effective treatment exists for DH. Understanding of the pathogenesis of 
the disease is therefore essential for development of treatment protocols. Suggestions 
made here about the pathogenesis of DH are based on findings of mononuclear 
inflammation in the liver tissue and a significant correlation between inflammation and 
MHC class II expression in hepatocytes. Another important observation is that different 
staining patterns of MHC class II molecules in hepatocytes occur at different stages of 
the disease.  
 
Within the immune system, MHC class II has a dual function. In the thymus, it is 
involved in the deletion of T-cells capable of reacting with self-antigens (Janeway et al. 
1999a). This deletion is, however, imperfect. All living beings have autoreactive T-cells 
that are capable of reacting with autoantigens. In the periphery, MHC class II has a 
major role in presenting antigens to CD4+ T-cells (Mellins 1992, Tizard 1996 Day 
1999). The results obtained in this study suggest that DH is an autoimmune liver disease 
that affects genetically susceptible Dobermans. The susceptibility is based on the type 
of MHC class II molecules that the individual produces. Dobermans whose MHC class 
II antigen complex interacts, with the help of co-stimulatory signals, with the T-cell 
receptor on T-cells, causing their activation, are prone to development of DH.   
 
In humans, an inducing agent is generally needed to initiate the autoimmune response 
(Czaja 2002). An environmental agent, e.g. a microbe, is assumed to be responsible for 
molecular mimicry, where the protein fragment from an infectious agent presented to 
the immune system will closely resemble a part of a self-protein. As a result of 
molecular mimicry, the activated immune system will not only attack a protein fragment 
from an infectious agent but also the protein fragment of a self-protein.  
 
An environmental trigger could also cause the initial mononuclear cell infiltration in 
DH. Cytokines produced by these cells then further induce expression of MHC class II 
in hepatocytes. This suggestion is based on findings in two Dobermans for which both 
biopsy and autopsy samples were obtained and mononuclear cell infiltrations were 
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present. While MHC class II expression was not observed in the biopsies, it was noted 
in autopsies of both dogs.     
 
The target cell in DH remains obscure (Thornburg 1998). Here, in 87% of biopsies 
taken in the subclinical stage of DH and in 100% of autopsies, MHC class II expression 
was seen in hepatocytes. MHC class II expression in hepatocytes is a persistent 
phenomenon, and expression seems to increase as the disease progresses. Hepatocytes 
of control Dobermans did not express MHC class II. This expression in DH indicates 
that in hepatocytes a specific antigenic peptide has become bound to the MHC class II 
molecule. Hepatocytes appear to be the target cells of this disease. 
 
In the present study, a correlation was observed between the extent of mononuclear cell 
inflammatory reaction and expression of MHC class II in hepatocytes. Certain cytokines 
are known to induce expression of MHC class II genes in non lymphatic cells. 
Moreover, bile duct epithelial cells, despite obvious portal inflammation, only in few 
cases and weakly expressed MHC class II. Although bile duct epithelial cells do not 
normally express MHC class II, in primary biliary cirrhosis and sclerosing cholangitis, 
both classified as autoimmune diseases in humans, they do so (Ballardini et al. 1984, 
Broome et al. 1990). These findings indicate that in DH cytokines produced by 
mononuclear inflammatory cells induce an aberrant expression of MHC class II in 
hepatocytes but not in bile duct epithelial cells. 
 
In biopsies, MHC class II expression was primarily seen in the cytoplasm of 
hepatocytes, while in autopsy samples, expression was most prominent on cell surfaces.  
These findings indicate that as long as the MHC class II molecule and antigen are in the 
cytoplasm, the hepatocyte is safe from an immune system response. When the MHC 
class II:autoantigen complex reaches the cell surface, however, the immune system 
recognizes the complex and becomes activated. The lymphocytes that react with 
hepatocytes expressing MHC class II on their cell surfaces appear to be CD4+ T-cells. 
In autopsy samples, the most prominent MHC class expression on cell surfaces of 
hepatocytes was adjacent to piecemeal and bridging necrosis areas. This finding 
suggests that CD4+ T-cells were activated and had started an immune attack against 
hepatocytes. This is known as “MHC class II restricted activation of T-cells” (Janeway 
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et al 1999b). These T-cells appear to be autoreactive, suggesting that DH is a T-cell-
mediated disease.   
 
Dogs with subclinical DH can remain asymptomatic for several months or years, despite 
plasma levels of their liver enzymes being elevated. It is therefore probable that after the 
initial induction of the autoimmune reaction by an environmental agent a subsequent 
stressful stimulus, such as pregnancy, enhances liver destruction.   
 
Although CD4+ T-cells are responsible for initiating the immune reaction, they are not 
capable of causing the final destruction of hepatocytes. Instead, after the interaction 
between the MHC class II:autoantigen complex on hepatocytes and T-cell receptors on 
CD4+ T-helper cells, the T-helper cells become either Th1- or Th2-cells. These cells are 
differentiated by the cytokines they secrete (Day 1999). Th1-cells are mainly 
responsible for activating macrophages. They can also activate CD8+ cytotoxic T-cells. 
Th2-cells, by contrast,  are the most effective activators of B-cells (Janeway et al. 1999). 
Therefore, in DH, the final mechanism causing the destruction of hepatocytes depends 
on the type of  cytokines secreted by activated T-helper cells (Fig 5).  
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Figure 5. Hypothesis for the pathogenesis of DH. 
 
A. An environmental trigger (e.g. a microbe) causes the initial mononuclear 
cell infiltration. 
B. Cytokines produced by the inflammatory cells induce the expression of 
MHC class II genes of hepatocytes in individuals who are genetically 
suspeptible to DH. The environmental agent is responsible for molecular 
mimicry in which the activated immune system will attack not only protein 
fragments from  infectious agents but also fragments of native proteins.  
C. While the MHC class II molecule and autoantigen are in the cytoplasm, 
the hepatocyte is safe from an immune system response. However, when the 
MHC class II:autoantigen complex reaches the cell surface, the immune 
system will recognize  the complex and become activated. 
D. The lymphocytes that react with hepatocytes expressing MHC class II 
molecules on their cell surfaces are CD4+ T-cells. 
E. After the interaction between the MHC class II:autoantigen complex on 
hepatocytes and the T-cell receptors on CD4+ T-helper cells, the T-helper 
cells become activated and start to secrete cytokines. The final mechanism 
causing the destruction of hepatocytes depends on the type  of  cytokines 
secreted by activated CD4+ T-helper cells as well as the types of cells 
(macrophages, B-cells, or CD8+ cytotoxic T-cells) stimulated. 
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10.  CONCLUSIONS 
 
Dobermans with subclinical chronic hepatitis can be identified by regular testing of 
serum ALT and AP levels. ALT was the best screening parameter for DH because it 
was the first liver enzyme to rise. Unlike ALT, AP levels can be normal in the initial 
stages of the disease. Serum ALT and AP values can be abnormal for several months or 
years before a dog shows clinical signs. During the subclinical and clinical stages the 
ALT and AP values frequently fluctuate. Despite fluctuation, enzyme values of dogs 
here did not return the normal range. The normalization of serum ALT concentration is 
rare even in the end-stages of the disease.  
 
ALT and AP are not good prognostic indicators of disease progression from the 
subclinical to the clinical stage. Total bilirubin is a better indicator. In dogs with 
subclinical DH, total bilirubin levels were normal for several months or years despite 
increased ALT and AP values. When dogs exhibited clinical signs of liver failure, the 
total bilirubin level was invariably abnormal. Total bilirubin values should therefore be 
routinely tested in dogs from suffering either subclinical or clinical DH. 
 
A Doberman who has consistently elevated ALT values and whose liver biopsy reveals 
mononuclear inflammation in the parenchymal and portal areas, absent or minimal 
piecemeal and bridging necrosis, and increased Cu levels is suffering from subclinical 
DH. The disease is progressive in nature, leading to histological alterations typical of 
for chronic hepatitis, including piecemeal and bridging necrosis, fibrosis, and cirrhosis.      
 
Increased Cu levels of the liver were noted in both the subclinical and the clinical stages 
of DH. Cu was initially observed in the parenchymal area, and in the later stages of the 
disease, adjacent to piece meal– and bridging necrosis areas. By measuring Cu levels in 
different stages of the disease, Cu content was found to increase with disease 
progression.  
 
In the subclinical stage, no signs of chronic cholestasis were present despite increased 
hepatic Cu levels. Total bilirubin values were normal. The Cu was mainly situated in 
the parenchymal areas, and the periportal areas were intact. Bile plugs were not 
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detected. Thus, chronic cholestasis as a reason for Cu accumulation in the liver in DH is 
unlikely.  
 
Increased hepatic Cu content was associated with tissue inflammation in the liver. Cu 
accumulation was assumed to be due to tissue inflammation and not vica versa. Cu is 
proposed to accumulate in hepatocytes because mononuclear inflammation disturbs the 
movement of Cu  from hepatocytes to the bile canaliculus. 
 
MHC class II, a protein expressed by professional APCs, presents processed antigens to 
T-cells. Hepatocytes, which normally do not express MHC class II molecules, do so in 
DH. The MHC class II expression by non professional APCs can be due to microbes, 
drugs, toxins, or  autoimmunity. In DH, drugs and toxins were ruled out. The most 
probable explanation for abnormal MHC class II expression by hepatocytes in DH is 
autoimmunity, with the presented antigen being an autoantigen of hepatocytic origin. 
However, primary viral infection cannot be completely ruled out.  
 
The MHC class II expression in hepatocytes strongly indicates that hepatocytes are the 
target cells of DH. An environmental trigger, e.g. microbe, could cause the initial 
mononuclear cell infiltration. Cytokines produced by these cells then further induce 
expression of MHC class II molecules in hepatocytes. An environmental agent probably 
causes molecular mimicry, whereby the protein fragment of an infectious agent 
presented to the immune system closely resembles part of a self-protein. As a result, the 
activated immune system will not only attack the protein fragment of an infectious 
agent but also the protein fragment of a self-protein. As long as the MHC class II 
molecule and autoantigen remain in the cytoplasm, the hepatocyte is safe from an 
immune system response. When the MHC class II:autoantigen complex reaches the cell 
surface, however, the immune system recognizes  the complex and becomes activated. 
 
Lymphocytes that react with hepatocytes expressing MHC class II on their cell surfaces 
are CD4+ T-cells. This indicates that these T-cells are autoreactive and that DH is a T-
cell-mediated disease. Although CD4+ T-cells are responsible for starting the immune 
reaction, they are not capable of causing the final destruction of hepatocytes. The final 
mechanism causing the death of hepatocytes depends on the types of cytokines secreted 
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by the activated CD4+ T-helper cells and the types of cells are stimulated. These cells 
can be macrophages, B-cells, or cytotoxic T-cells. 
 
The high prevalence of chronic hepatitis in Dobermans indicates a genetic 
predisposition, which is somehow associated with MHC class II genes. Dobermans 
whose MHC class II antigen complex interacts, with the help of co-stimulatory signals, 
with the T-cell receptor on T-cells, causing their activation, are prone to the 
development of DH. 
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